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ABSTRACT 
B lymphocytes are a type of white blood cells, belonging to the adaptive arm of the immune 
system and involved in creating immunological memory. B cells function in the humoral 
immune system by secreting antibodies which can bind pathogens to prevent them from doing 
further damage and to help other immune cells to target them. It is highly important that the 
immune system can distinguish self from none-self, since an immune response to self-antigens 
would cause the immune system to attack the hosts own healthy cells and tissues. The 
development of different B cells subsets is highly complex and both differentiation and 
proliferation is under strict transcriptional control. Defects in lymphopoiesis can lead to serious 
disorders like immunodeficiency, allergy, malignancy and autoimmunity. 
In Study I we wanted to create a B1 cell-deficient mouse model by deleting the transcription 
factor Arid3a in a B cell-dependent manner. B1 cells are known to secrete natural antibodies 
which have shown to be atheroprotective and play other important roles in pathogenic 
conditions and diseases affecting a large number of people in the world. Our results 
demonstrate that Arid3a is required for specific immune responses and for the generation of 
normal cell numbers in a subset-dependent manner. 
In Study II we were interested in understanding the function of germinal center formation in 
rheumatoid arthritis. We wanted to explain the involvement of antibody production and to 
target germinal center B cells, highly involved in the development and progression of this 
disease. Our results show that germinal center B cells are essential for experimental arthritis 
and targeting them could help when establishing more refined B cell-depleting therapeutics for 
clinical arthritis. 
In Study III we wanted to understand the role of the adaptive immune system throughout the 
disease course of multiple sclerosis. B lymphocytes are known to be highly involved in 
influencing this disease, however the role of germinal center B cells has been unknown. To 
illuminate the function of germinal center responses, we induced experimental autoimmune 
encephalomyelitis in a murine model lacking germinal centers. We show that the functions of 
germinal center B cells is antigen-dependent and can both protect and promote disease.  
In Study IV we deleted Apoe in a novel atherosclerotic murine model, in order to induce acute 
hypercholesterolemia in adult mice. Currently, there exists various atherosclerotic mouse 
models, however atherosclerosis differs between human and mouse and therefore we were 
interested in interrogating this disease in an inducible murine model. Our results demonstrate 
that the acute loss of Apoe triggers an autoimmune response, accelerating atherosclerosis. 
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AIMS OF THE THESIS 
The aims of this thesis was to investigate the implication of B lymphocytes in different 
autoimmune conditions and to clarify the role of different mature B cell subsets in various 
inflammatory disorders using genetically modified murine models. Our specific scientific goals 
were to: 
 
Study I Create and investigate a pure B1 cell-deficient mouse model by conditionally 
deleting the transcription factor Arid3a in a B cell-dependent manner.  
Study II Clarify the function of germinal center B cells and antibodies in rheumatoid 
arthritis by studying collagen-induced arthritis in two germinal center-deficient 
mouse models. 
Study III Understand the critical functions of B cells in the disease course of multiple 
sclerosis by inducing Experimental autoimmune encephalomyelitis in a murine 
model lacking germinal centers. 
Study IV Investigate the development and early inflammatory response of autoimmune 
conditions and cardiovascular disease, by deleting Apoe in the adult mouse in 
order to induce acute hypercholesterolemia.
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
The immune system has a critical function in helping to protect us from pathogens. It consists 
of physical and chemical barriers, molecules, cells and tissues, coordinating immune responses 
against bacteria, viruses and other microorganisms 156. When pathogens break through these 
barriers, an inflammatory response is almost immediately induced, characterized by heat, 
redness, local swelling and pain, due to dilation of the blood vessels and accumulation of 
proteins and cells at the site of the infection. The innate immune system is mainly activated at 
the site of infection where the pathogens invade the host, while the adaptive immune system is 
activated in peripheral lymphoid organs 1. Together, both parts of the immune system work fast 
and efficiently to eliminate the foreign microbes 7. 
1.1.1 The innate immune system 
The first part of the defense against microbes and tissue injury is the innate immune system. 
When an infection occurs, the components of the innate immune system are rapidly activated 
upon encountering the pathogens to maintain a healthy microenvironment 156. This first line of 
the immune system is generally not specific to certain pathogens, and depends therefore on 
molecules and cells recognizing conserved characteristics of pathogens that are not present in 
the host. The innate immune system is estimated to be able to recognize up to 103 different 
molecular patterns 6, 113 and reacts rapidly to any foreign pathogen encroaching the host. The 
molecules and cells of the immune system are many and become quickly activated when 
recognizing a foreign pathogen.  
The innate immune cells and molecules include phagocytic cells, antigen presenting cells, 
natural killer cells, natural antibodies, the complement system, and physical barriers such as 
epithelial cells. Epithelial barricades, such as the skin and the interior mucus-covered surfaces 
in the lung and gut, provide protection against potential pathogens and mechanical and 
chemical damage 1. These integral components of the innate immune system also produce 
chemokines and cytokines and have the ability to recognize and deal with danger signals. From 
time to time, microorganisms break though the epithelial surfaces, challenging the innate and 
adaptive immune system. For the immune system it is important to recognize and destroy the 
pathogens without damaging the host, and so the immune cells need to distinguish non-self 
from self  7, 156. 
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The soluble proteins of the complement system, circulating in the extracellular fluid and in the 
blood, are mostly inactive until an infection triggers an activation. The early components of the 
complement system are activated first and consist of the classical, alternative and lectin 
pathway, all of them activating the main component of the complement C3 156. Since these 
early components are proenzymes, the three pathways all lead to cascades of molecule 
cleavages, resulting in binding to the surface of foreign pathogens, thus helping to the next 
reactions in the immune system. The complement system was first discovered to be an effector 
arm of the antibody response, however complement is also activated without the presence of 
antibodies 39. 
Humans and most of the mammalian species have membrane-bound glycoproteins called Toll-
like receptors (TLRs), which are mainly expressed in myeloid cells, but also found in other cell 
types. TLRs recognize certain ligands, inducing inflammatory cascades 118. Upon activation, 
cytoplasmic Toll/IL-1 receptor (TIR) homology domains signal and engage further molecules 
to activation. These receptors are together called pattern recognition receptors (PRRs), since 
they recognize certain structural patterns. The structures of the microorganisms recognized by 
the innate immune system are named pathogen-associated molecular patterns (PAMPs), but 
are not necessarily the final antigen to be presented by the antigen presenting cells (APCs) 116. 
PRRs are able to induce phagocytosis, inflammation and maturation of APCs, the latter 
providing and important link between the innate and adaptive immune system 118, 160, 263. 
B1 cells belong to a subset of B cells that produce antibodies that react against microbes passing 
through the intestine walls, amongst others, and are thus predominantly found in the mucosal 
tissues and the peritoneal cavity. These cells are considered innate-like lymphocytes 126, 
although B cells in general are a part of the adaptive immune system. In healthy mice, most of 
the IgM circulating in the blood, is secreted by B1 cells. These natural antibodies recognize 
carbohydrates present on many bacteria 1. Additionally, phagocytic cells, like long-lived 
macrophages or short-lived neutrophils, are quickly at the site of inflammation when an 
infection occurs. They have receptors, such as Toll-like receptor (TLRs) at the cell surface, 
recognizing foreign pathogens and engulfing them.  
After the phagocytic cells have taken up the pathogens, the newly formed phagosomes get 
acidified and lysosomes help to degrade the pathogens 156. Macrophages secrete cytokines, like 
Tumor necrosis factor (TNF), and chemokines, like CXCL1, CXCL2, and CXCL5, attracting 
neutrophils, monocytes and dendritic cells to the location 254.  
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Once the dendritic cells pick up epitopes from the pathogens, they transport them to nearby 
lymph nodes, presenting them to lymphocytes and thus activating the adaptive immune system. 
In humans and other vertebrates, these immune responses are required to initiate the more 
specific adaptive immune responses 1. 
1.1.2 The adaptive immune system 
The second line of the immune system is the adaptive immunity, which is acquired throughout 
life, and activated after an immune response has been initiated. Compared to the innate immune 
system, the adaptive immune system is slow to react on the first exposure to a new foreign 
pathogen, however it is very specific and can respond to millions of different foreign antigens 7. 
Lymphocytes, called B and T cells, are responsible for the specificity of the adaptive immune 
system. They circulate in blood and lymph, and are found in organs like spleen, thymus and 
lymph nodes. Lymphocytes are committed to a certain antigen or hapten, and after the first 
exposure to this antigen, they develop a memory that results in a quick and more effective 
response next time the lymphocytes encounter with the same antigen 156. In humans, the 
adaptive immunity consists of about 2 x 1012 lymphocytes 7, usually only responding after the 
innate immune system is activated. The innate immunity depends on the previously mentioned 
PRRs, recognizing foreign immuno-stimulants and activating cascades of immune responses. 
Some of these cascades result in the production of extracellular signaling molecules promoting 
and activating the adaptive immune system. 
Dendritic cells, present in almost all vertebrates, are professional APCs belonging to the innate 
immune system, recognizing and engulfing foreign pathogens where they infect the host, and 
then migrate to nearest peripheral lymph nodes to present epitopes directly to T lymphocytes. 
This initiates an adaptive immune response, resulting in T cells responding to the epitopes. 
Some of the activated T cells migrate to the site of the infection, helping other cells to defeat 
the pathogens, while other T cells stay in the lymphoid organs to help and activate B cells 156. 
These B cells can terminally differentiate into plasma cells and secrete antibodies that spread 
throughout the body, coating the invading pathogens and helping the phagocytic cells to target 
them more efficient. 
Both B and T cells develop from pluripotent hematopoietic stem cells (HSCs) located in the 
liver of the fetus and in the bone marrow of the adult, referred to as central lymphoid organs. 
T cell precursors then migrate to the thymus and develop further in that central lymphoid organ, 
while B cells develop from the hematopoietic stem cells (HSCs) in the hematopoietic tissues 
in liver and bone marrow 1.  
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Almost all lymphocytes fail to fully develop into a functioning B or T cell, whereas a small 
number migrate from the central to the peripheral lymphoid organs where they have the 
possibility to react to foreign invading agents, be activated, proliferate and mature into effector 
cells 7. T cells can roughly be divided into cytotoxic and helper T cells, the first one terminating 
infected cells, and the latter one helping to active B cells, macrophages and cytotoxic T cells 
with the help of secreted local mediators, named cytokines, and costimulatory proteins on their 
surface. The binding of antibodies to the foreign epitopes also help other cells like macrophages 
to target them for phagocytosis.  
As a part of the adaptive immune system, B cells play central roles in humoral immunity and 
protect, with the help of an enormous diversity of antibody specificities, against an almost 
unlimited variety of pathogens 7. When B lymphocytes develop in the central lymphoid organs, 
they are committed to respond to a certain epitope, expressing it through cell-surface receptors 
that specifically fit to that antigen. When this particular antigen later is encountered by the B 
cell in a peripheral lymphoid organ, it binds to the receptor, leading to activation, proliferation 
and differentiation of the lymphocyte, making the adaptive immunity antigen-specific 7.  
After the initial exposure with a pathogen, the adaptive arm of immunity creates a memory, 
being the reason why lifelong immunity to common diseases is developed. Comparing the 
primary immune response, the first exposure to a new foreign antigen, with the secondary 
immune response where the immune system has already created a memory, the primary 
immune response takes several days to react, rises exponentially and quickly, and then slowly 
declines. However, next time the immune system encounters with the same pathogen, the 
secondary immune response responds fast and strong, due to the immunological memory that 
has been created 7. In order to prevent lymphocytes from responding to self-antigens, the 
lymphocytes are controlled during development. Lymphocytes hat show tendencies to bind to 
self are either induced to destroy themselves, get inactivated or suppressed, or their receptors 
are altered. Nevertheless, defects in lymphopoiesis, differentiation or function exist, resulting 
in severe disorders like immunodeficiency, malignancy, allergy and autoimmunity. 
1.1.3 Autoimmunity 
Autoimmunity is a condition where the adaptive immune system breaks down the tolerance to 
self-antigens, causing harm to organs or components of the blood, that is, it fails to differ 
between non-self and self, and thus attacks self-components instead of foreign pathogens. 
There are several hypotheses to why autoimmunity develops, however the main factors are 
environmental stimuli, infections, injuries and inheritance of susceptibility 1.  
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Rare mutations are also suggested to have a large impact on the development of autoimmune 
diseases 122, 276. Studies in animal models and genome-wide association studies (GWAS) have 
further increased our knowledge about common polymorphisms of genes contributing to 
various autoimmune diseases 19, 44, 103, 162, 175. Hundreds of gene polymorphisms associated to 
autoimmunity have been identified by GWAS 57, 178, 267, the majority of these genetic changes 
predicted to affect immune functions. The major histocompatibility complex (MHC) is a very 
gene-dense region, and MHC loci are known to be the strongest reported associations in most 
diseases 178. 
Autoimmune diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and 
multiple sclerosis (MS) are characterized by the development of autoantibodies and the 
presence of autoreactive immune cells 275, and although our knowledge grows, as well as the 
increasing disease prevalence 95, 112, the etiology of several common autoimmune diseases 
remains unknown, due to heterogeneous and multifactorial reasons. Twins, especially 
monozygotic twins, have shown to be more prone to develop the same disease compared to 
other family members, elucidating the importance of inheritance and genetics in susceptibility 
to autoimmune diseases 17, 45, 60, 82, 174. Other studies report epigenetics to play an important role 
in development of many autoimmune diseases 96, 134, 172, 242, 243.  
Important studies propose B lymphocytes to be highly involved in autoimmune disease, 
especially those associated to humoral autoimmunity. Alterations in B cell signaling might 
initiate or promote autoimmunity, due to defects in genes involved in B cell function encoding 
signaling effectors, receptors and downstream transcriptional regulators of the BCR, cytokine 
receptors, CD40 or TLRs 111. B lymphocytes express both innate pattern-recognition receptors 
like TLRs, and clonally rearranged antigen receptors, called B cell receptors (BCRs) 192. 
Anti- viral antibody response are dependent on TLR signals from B cells through the adaptor 
protein MyD88 105, however dual activation of TLRs and BCRs can also increase the risk of 
autoimmunity, since TLRs on B lymphocytes respond to endogenous antigens 192. Both TLR 
and BCR activation have protective functions against infections, but also have potential to 
promote autoimmune disorders, thus these signaling pathways need to be strictly regulated. 
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Figure 1. Schematic illustration of systemic autoimmunity. 
 
Altered B cell signaling increases the risk of developing autoimmune disorders by 
modifications of negative and positive selection during B lymphopoiesis. Nevertheless, this 
does not immediately lead to autoimmune disease, since autoreactivity alone is rarely sufficient 
for developing disease. It is thought that formation of germinal center (GC) B cells that produce 
autoantibodies, generated from naïve or mature B lymphocytes, is a crucial second step for 
disease development. Subsequently, autoimmune GC B cells generate long-lived plasma cells, 
secreting class-switched autoantibodies, as well as memory B cells that are able to contribute 
in forming new autoimmune GCs and extra-follicular self-reactive B cells. It has also been 
suggested that autoimmune GCs promote the generation of autoreactive T follicular helper 
cells, which contribute to the formation of new autoimmune GCs 51, 189. They could also have 
additional functions than solely providing help to B cells.  
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1.2 B CELL SUBSETS AND DEVELOPMENT 
1.2.1 Early B cell development 
During early embryonic development, pluripotent hematopoietic stem cells (HSC) migrate into 
the fetal liver. These HSCs can differentiate into B cells, as well as other immune cell types, 
populating the lung, epithelia and lymphoid tissues in the gut 237. Fetal liver predominantly 
generate long-lived B1a cells and their precursors disappear in the early stages of life 28.  Short-
lived B1b cells, derived from the HSCs in the bone marrow, have similar characteristics as the 
B1a cells. However, precursors of B cells generated in the bone marrow can not develop into 
B1a cells later in life. The majority of B cells in the adult are of the B2 type and are generated 
in the bone marrow, migrating to spleen and lymph nodes 87, organizing B cell follicles and 
developing into marginal zone B cells found in the marginal zone of the spleen. The bone 
marrow maintains the ability to repopulate the host throughout life, although the numbers of 
HSCs decrease with increasing age. The differences between hematopoietic development in 
fetal liver and adult bone marrow have been demonstrated by several important experiments 
169. After birth, the bone marrow (BM) becomes the major site for continuous B lymphopoiesis. 
Self-renewing HSC give rise to progenitor cells which undergo lineage commitment and 
develop through multipotent progenitors (MPP) followed by common lymphoid progenitors 
(CLP), pro-B, pre-B and immature B cells 5.  
Gene rearrangements supports life-long generation of B cell repertoires 135, capable of 
recognizing antigens. The development of these repertoires critically depends on signaling 
molecules playing important roles in proliferation, differentiation, gene rearrangements, 
survival and apoptosis. Immunoglobulin gene rearrangement is important for B cell 
development and is regulated by several important transcription factors, such as PU.1, E2A, 
EBF and Pax5 38, 54, 194, 199, 238.  
Recent studies have shown that lineage skewing begins earlier than the CLP stage 107, 119, 138, 
238, 270. However B cells fully commit to the B lineage at the pro-B cell stage. This continuous 
B cell lymphopoiesis proceeds throughout life, although output decreases with age. Before B 
cell maturation, during differentiation from CLPs to pro-B cells, recombination activating 
genes 1 and 2 (Rag 1 and Rag 2)  and terminal deoxynucleotidyl transferase (TdT) promotes 
stepwise V(D)J-rearrangement in the immunoglobulin heavy chain (IgH) locus, that determine 
the B cell receptor composition 234. In order to achieve a balance between specificity against 
pathogens and avoiding autoreactivity, B lymphocytes are screened at a number of checkpoints 
during lymphopoiesis for their level of autoreactivity 146.  
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Screening takes place after differentiation of pro-B into pre-B cells. The surrogate light chain 
(SLC) probes IgH fitness to pair with the immunoglobulin light chain (IgL), and thus a 
pre– B cell antigen receptor (pre-BCR) complex forms. The IgH chain of the pre-BCR is also 
checked for autoreactivity. The pre-BCR shuts down expression and activity of the enzyme 
machinery which catalyzes the rearrangements of the H-chain gene segments, also known as 
allelic exclusion 231, preventing expression of two IgH chains with two different specificities 
by the same cell. Thereafter, if the variable region of the IgL chain fits the variable region of 
the IgH chain, immunoglobulin M (IgM) is displayed as a B-cell receptor (BCR) on immature 
B cells, with each B lymphocyte expressing one BCR. 
Defects in distinguishing between these could lead to autoimmune disease. Normally, when 
immature B cells migrate to the spleen, they only respond when encountering antigens and 
thereby proliferate and differentiate into memory B lymphocytes and plasma cells. Apoptosis 
and anergy can also be induced by antigenic stimulation 197, screening B cells for potential 
autoreactivity and eliminating them before they become mature. In patients with rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE), reduction of autoreactive B cells can 
fail at this peripheral checkpoint 273. 
1.2.2 Late B cell development 
During the stages of B cell differentiation, IgM is first expressed on the cell surface of immature 
B cells in the bone marrow, from very low to high levels of surface IgM. Immature B cells also 
express surface markers like CD19, intermediate levels of B220, and they will after maturation 
express CD21 or CD23, with a few of them also expressing low levels of surface IgD 34. In 
order for immature B cells to migrate from the bone marrow to peripheral lymphoid organs 
such as the spleen, they have to express high levels of IgM on the surface. IgM-expressing B 
cells transit to the spleen through the terminal branches of central arterioles 9, 10, 133, whereas B 
cells that are negative for surface IgM do not appear in the spleen. Experiments show that 5–
10% of newly generated immature B lymphocytes enter the pool of long-lived mature B 
lymphocytes 8-10, 37, 70, 132, 197, 198, 200. 
Immature B lymphocytes can be distinguished from mature B lymphocytes in the spleen, due 
to their low expression of B220 and IgD, and their high heat stable antigen (HSA), CD93 and 
IgM expression 9, 10. The immature B cell compartment in the spleen has previously been found 
to be subdivided into two different B cell subsets, transitional 1 (T1) and transitional 2 (T2) 
B cells 132.  
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T1 B cells are characterized by high expression of surface IgM, low expression of IgD, and 
absence of CD21 and CD23, while T2 B cells express high levels of IgM, but are positive for 
IgD, CD21, and CD23. A third subset of transitional B cells in the spleen has been found, 
termed transitional 3 (T3) B cells 8. In the spleen, transitional B lymphocytes complete 
maturation by developing either into follicular or marginal zone (MZ) B lymphocytes. MZ B 
cells have BCRs on the surface that bind to blood-borne antigens, like epitopes from bacteria 
and lipid antigens. In combination with Toll-like receptor (TLR) signals, induced by 
recognizing pathogen-associated molecular patterns, MZ B cells differentiate into plasma cells, 
secreting IgM and creating a defense against pathogens in the spleen. For activation of follicular 
B cells, transportation of antigens into B cell follicles of secondary lymphoid organs is required. 
Follicular B cells present antigens on Major histocompatibility complex (MHC) class II to T 
helper cells, upon antigen recognition and activation, in order to receive additional activation 
signals in form of CD40L and cytokines.  
 
Figure 2. Schematic illustration of B cell development. 
 
Interaction between B and T lymphocytes promotes differentiation of activated follicular 
B lymphocytes into dividing blasts that form germinal centers (GC). Interaction with GC 
stromal cells and follicular T helper cells allows GC B cells to undergo immunoglobulin class 
switch recombination (CSR) to modify the specificities of the BCRs by somatic hypermutation 
(SHM), and to differentiate into memory B lymphocytes with surface IgG and IgE.  
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They can also develop into long-lived plasma cells, producing class-switched antibodies. B 
lymphocytes are the source of the humoral immune system and have been thoroughly studied 
due to their role in promoting inflammatory responses.  
Nevertheless, there exist B cell subsets known to have anti-inflammatory roles. Regulatory B 
cells (Bregs) have been demonstrated to inhibit inflammatory responses several years ago 151, 
and since then, other roles for Bregs in different autoimmune and allergic conditions have been 
found, as well as several diverse mechanisms through which Bregs can reduce inflammation 11, 
27, 64, 68, 79, 81, 140-142, 233, 245, 264. Bregs are immunosuppressive cells supporting immunological 
tolerance. They suppress inflammation through production of the anti-inflammatory cytokine 
IL-10, which is one of the most studied mechanisms regarding regulatory B lymphocytes 149, 
150, 171. IL-10 secreting B cells were first characterized in an induced mouse model of contact 
hypersensitivity, where immune cells, like T cells, provoked inflammation 264. During the 
process of an infection, the inflammatory response is crucial for the clearance of pathogens and 
initiation of protein cascades involved in the healing of wounds 145.  
In individuals with chronic inflammation, the immune system is constantly activated, often 
shown by deficiency in number and function of Bregs at the site of inflammation and in the 
circulation 158. Bregs prevent expansion of pathogenic T cells and other pro-inflammatory cells 
through the production of IL-35, IL-10 and transforming growth factor beta (TGF-β). The 
usage of genetically modified mice lacking B cells, in particular IL-10-secreting B cells, has 
shown that defective function and development of Bregs leads to chronic inflammation 68, 258, 
suggesting Bregs to be future therapeutic targets in cases of autoimmunity, infection and 
cancer. 
1.2.3 Transcription factors important in B cell development 
The Ikaros transcription factor family control the specification of HSCs to the lymphoid 
lineage. Ikaros zinc fingers induce transcription of genes involved in cell cycle regulation, 
pre- BCR signaling and V(D)J-rearrangement 67. Experiments in mice have shown that when 
the gene encoding Ikaros, Ikzf1, is deleted, the development of CLPs is impaired. This leads to 
blockage at early stages of B cell lymphopoiesis, delaying differentiation of thymocytes which 
are hematopoietic progenitors present in the thymus 75, 271. Ikaros has also been shown to be a 
major negative regulator of B1 lymphocyte function and development 136. There are additional 
transcription factors with DNA binding domains containing several Zn-fingers, besides 
members of the Ikaros family, for example BLIMP-1, BCL-6 and GFI, MIZ-1 and CTCF, 
which regulate critical steps in B cell development 121, 154, 185, 195, 239, 268.  
  21 
The most crucial steps in early B cell lymphopoiesis are however regulated by the transcription 
factors E2A, EBF1, FOXO-1 and PAX5, including V(D)J-rearrangement and expression of the 
pre-BCR. The specification of the CLPs to the B cell lineage is initiated by E2A and EBF1 159, 
168, 218. In Ebf1 or E2A knockout mice, HSC fail to reach the pro-B cell stage and thus B 
lymphocytes can not develop 30, 128. RUNX1 and C-MYC regulate transcription of EBF1 216, 
240, and EBF1 and E2A induce expression of several B cell lineage determining genes, such as 
Foxo1 129, 252, 274, which is needed to activate transcription of Rag1 and Rag 2, required for 
heavy- and light chain gene rearrangement 58. PAX5 is involved in B cell lineage commitment 
of precursor cells, shown in experiments with Pax5 knockout mice, since pro-B cells are 
uncommitted in these mice and can develop into many different hematopoietic lineages 41, 56, 
166, 167. 
1.2.4 The transcription factor Arid3a 
ARID3A is one of 15 members of the A+T rich interactive domain (ARID) family of DNA-
binding proteins, many of which are shown to have epigenetic regulatory roles 120, 180, 256. These 
proteins bind to A+T rich sequences on the DNA and are members of greater chromatin 
modulatory complexes. Arid3a is one of few members for which a DNA-binding recognition 
site has been found. Arid3a was first cloned through homology with the orthologue Dril1 in 
Drosophila, and later re-identified as a protein related to E2F (E2FBP). Known as a B cell 
regulator of immunoglobulin heavy chain transcription (BRIGHT) in mouse, this 70 kDa 
DNA-binding protein has been characterized as a transcription factor that up regulates 
immunoglobulin heavy chain (IgH) transcription in activated B lymphocytes as part of a greater 
protein complex that contains the enzyme Bruton's tyrosine kinase (BTK) and the ubiquitously 
expressed transcription factor II-I 247-249.  
The expression of Arid3a is limited in adults, however it is widely expressed in embryo and 
fetus, having important regulatory functions in embryonic stem cell differentiation, 
highlighting novel roles for Arid3a in gene expression 12. The transcription factor ARID3A is 
thought to be restricted to cells of the B cell lineage within the immune system, yet others have 
demonstrated that Arid3a plays important regulatory functions in early hematopoiesis. Arid3a 
is expressed in both murine and human subsets of pre-B cells, transitional B cells, activated B 
cells, memory B cells and plasma cells. Nevertheless, most of the resting, naïve and mature 
peripheral B cells do not express Arid3a 165, 250. Innate-like B cells named B1 cells, 
predominantly found in the pleural and peritoneal cavities, have in previous studies been shown 
to express lower levels of ARID3A 36, 152, 164. Hence, the expression of Arid3a is thought to be 
strictly regulated at the level of transcription throughout B lymphocyte development. 
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1.3 DISEASE MODELS 
1.3.1 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease, characterized by 
synovitis, which leads to destruction of the cartilage and bones. The pathogenesis of RA is 
complex and involves both genetic and environmental factors initiating inflammatory 
responses resulting in swelling and destruction of the tissue. Studies have shown that a high-
risk genetic background together with environmental stimuli and epigenetic changes result in 
a cascade of inflammatory events causing activation of macrophages by autoreactive T cells, 
which leads to the release of pro-inflammatory cytokines like interleukin 1,6 and 17 (IL-1, 
IL- 6, IL-17) and tumor necrosis factor α  (TNF- α). 72, 108, 225.  
There are several immunotherapies that have shown to be successful in disease management, 
targeting cytokines, their receptors or other signaling components downstream 72, however the 
events that actually cause the recruitment of autoreactive lymphocytes is still under exploration. 
Recently, reactivity to citrullinated antigens in the initial pathogenesis has been elucidated in 
several autoimmune diseases, including RA, proposing citrullination to be of great importance 
in the process of epitope spreading and the emergence of auto-epitopes 35, 65, 155, 221. Detection 
of anti-citrullinated protein (ACP) antibodies is used for the diagnosis of RA, is a highly 
specific method and can be used even before the clinical disease onset 42.  
Animal models are essential for understanding the pathogenesis and induction of autoimmune 
disease and for being able to develop therapeutic interventions that can detain disease 
progression or even effectively treat the disease. Collagen-induced arthritis (CIA) is the most 
common and well-studied rodent model of human RA. CIA can be used for both rats and mice, 
and is induced by immunization of Type II collagen (CII), which is the main constituent 
collagen form in articular cartilage, previously identified in RA patients 48, 104, 229, 236. After 
disease onset, rodents develop a monophasic erosive polyarthritis, characterized by swelling of 
the joints in toes and wrists. Several features of RA is present in mouse CIA as well, like anti-
citrullinated peptide antibodies and rheumatoid factors, making this animal model suitable for 
studies of rheumatoid arthritis 215.   
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1.3.2 Multiple sclerosis 
Multiple sclerosis is a degenerative and demyelinating autoimmune disease of the central 
nervous system (CNS), involving mechanisms of both the innate and adaptive immune system. 
MS has a highly complex, heterogeneous pathogenesis, believed to result from interactions of 
polymorphic genes, epigenetic regulation and environmental factors such as smoking, 
commensal microbiota, virus infections, demographics and Vitamin D deficiency 22, 24, 49, 203, 
208, 210, 235. Genome-wide association studies (GWAS) have revolutionized the field of 
autoimmune disease 100, and more than 100 single nucleotide polymorphisms (SNPs) have been 
associated with MS 211. This polygenic disease can have several courses and different 
progression rates.  
The most frequent phenotype is relapsing-remitting MS (RRMS), which covers around 85% 
of newly diagnosed patients, characterized by phases of deterioration, followed by spontaneous 
remission. Initial RRMS most often develops into secondary progressive MS (SPMS), 
described as a progressive worsening of neurologic function without any remissions. About 
15% of newly diagnosed patients develop clinical primary progressive MS (PPMS), without 
any preceding relapses or remissions 80, 114, 170. There exists several different animal models of 
MS, however the most studied and best understood is the rodent model of Experimental 
Autoimmune Encephalomyelitis (EAE). Several therapies have been developed and tested 
using this rodent model of disease, such as Natalizumab (Tysabri), before going further into 
clinical trials 269.  
EAE, first time induced over more than 60 years ago, is an acute or chronic relapsing disease 
characterized by demyelination of axonal tracks throughout the central nervous system, leading 
to weakness and paralysis of the hind limb legs in rodents, followed by spontaneous 
remission173. In EAE, monocytes and T cells infiltrate the CNS, causing local inflammatory 
responses with proteins expressed by myelin-producing oligodendrocytes as targets. This then 
leads to demyelination of the axons and impaired axonal conduction. Currently, there are 
several pathophysiological types of EAE with different patterns of presentation, depending on 
which peptide or protein and which animal model that is being used. This disease model has a 
clinical course, which is characterized by a prodromal period of 10-15 days, followed by weight 
loss and paralysis of the tail and hind limbs, and finally proceeding to the other limbs. In some 
animal models, the disease follows a course similar to relapsing-remitting MS, which gives 
opportunities for immunomodulatory and mechanistic studies. 
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1.3.3 Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of the arteries, characterized by deposition 
and trapping of low-density lipoprotein (LDL) in the artery walls, and is the underlying cause 
of many cardiovascular disorders, such as stroke, myocardial infarctions and peripheral 
vascular disease. Both the innate and adaptive immunological arms are involved and the 
response is often due to hyperlipidemia 13 77, 204. In atherosclerosis, LDL is modified by a variety 
of enzymatic and non-enzymatic alterations, leading to cascades of inflammatory responses 
followed by recruitment of immune cells like T cells and macrophages 227.  Both cells of the 
immune system and cells of the vessel walls participate in atherogenesis, heavily influenced by 
genetics, lifestyle and diet, hemodynamics of the blood flow in the arteries and by plasma 
lipoproteins. 
A large number of inbred mouse strains have been crossed into the background of genetically 
modified atherosclerotic models, resulting in diverse susceptibility to develop atherosclerosis, 
and leading to the identification of genes involved in the determination of resistance and 
sensitivity  to atherosclerosis220, 232, 266. Mouse models of atherosclerosis are dependent on 
increasing blood plasma levels of LDL and very low-density lipoprotein (VLDL), and thus 
these murine atherosclerotic models are often based on genetic ablation of apolipoprotein E 
(ApoE) or the LDL-receptor.  
B-cell immune responses have been identified to be involved in atherosclerosis and coronary 
heart disease (CHD) 106. Functional roles of B cells in experimental atherosclerosis have been 
demonstrated by splenectomized Apoe knockout mice, showing that these mice develop 
aggravated atherosclerosis. Nevertheless, this effect could be reversed by transfer of educated 
splenic B lymphocytes. Transferring educated splenic B lymphocytes from older Apoe 
knockout mice both rescued the pro-atherogenic effect and reduced the size of lesions 33. 
Regulatory B cells (Bregs) have a different surface marker expression compared to other B 
cells and have been shown to be involved in autoimmunity, e.g. by the secretion of interleukin-
10 (IL-10) or direct interaction with pathogenic T cells 265. The role of Bregs in atherogenesis 
still remains to be characterized. 
Even though studies of currently existing atherosclerotic mouse models noticeably have led to 
a better understanding of atherogenesis, many features of present mouse models differ from 
the human disease 23, 53, 147, highlighting the importance of finding new murine models, better 
applicable to human atherosclerosis and the underlying mechanisms.  
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2 METHODOLOGICAL CONSIDERATIONS 
2.1 ANIMAL MODELS 
In our studies, we used several different murine models for investigating various autoimmune 
disorders, by the usage of the Cre/lox system. In this system, the exon of interest is flanked by 
loxp sites and driven under a promoter. When this promoter is transcribed, the enzyme Cre is 
produced, leading to cleavage at the loxp sites, thus deleting the flanked exon in all cells that 
express the promoter. In the first study, we obtained a conditional allele of Arid3a and deleted 
this allele in all cells expressing Mb1, also known as Cd79a, by using an Mb1-Cre line. Mb1 is 
known to be unique for B cells, and is expressed from early progenitors, throughout B cell 
development and differentiation 101. Hence the Arid3a was removed in all stages and subsets 
of B lymphocytes. 
In the second and third study, we were interested in studying the germinal center reaction in 
various inflammatory disorders. We deleted Pax5, using Cd23-Cre and Aid-Cre. PAX5 is 
essential for B cell function, so loss of this transcription factor disrupts B cell function. 144. 
CD23 is expressed on mature B cells and AID is characteristic for germinal center B cells. 
These deletions resulted in two conditional knockout models for mature and germinal center 
B cells.  
In the fourth study, we created an inducible mouse model of atherosclerosis. APOE is a protein 
involved in the metabolism of body lipids, and is found on LDL and VLDL particles where it 
functions as a ligand for the LDL receptor. Deleting the gene encoding for this protein results 
in hypercholesterolemia and subsequently atherosclerosis. To investigate the development of 
these lesions and the implication of the immune system, we used the Cre/lox system, which 
was activated in mice by administration of tamoxifen, thereby deleting the gene in all cells. 
2.2 GENOTYPING WITH POLYMERASE CHAIN REACTION 
Genotyping is a method which we frequently used for distinguishing experimental mice from 
littermate controls, as well as for putting together new breeding pairs of mice. By extracting 
DNA from a small ear biopsy, we could with the help of specific primers and polymerase chain 
reaction (PCR) amplify a sequence of interest, determine its length through gel electrophoresis, 
and hence get information about the genotype. 
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2.3 FLOW CYTOMETRY 
For the characterization of cell subsets and populations within an organ, we used flow 
cytometry and phenotypic markers. We stained single cell suspensions with carefully chosen 
fluorescently labeled antibodies, and expression of target antigens can define population of 
cells. Thereafter, we acquired these suspensions in a flow cytometer, where different lasers 
inside the machine detected the fluorescently labeled markers, thereby quantifying the surface 
receptors, while also distinguishing cells by size and granularity.  
This method is highly advanced and gives the opportunity to describe a wide range of cell 
populations, however it is important to work properly and wash the suspension thoroughly, 
since overstaining could give inaccurate results and cross-contamination easily occurs. It is also 
necessary to use unstained and single stained-controls for each marker, in order to compensate 
for the spill of fluorescence between the markers, when analyzing the results in a proper 
software. For analysis of flow cytometry-data, we used the software FlowJo. 
2.4 CELL SORTING AND DELETION ANALYSIS 
In order to confirm the deletion of the flanked exon in our first study, we sorted B cells with 
the help of Fluorescence-activated cell sorting (FACS) and specific markers. We then extracted 
RNA from the sorted cells, made cDNA, amplified the specific sequence of interest with PCR 
and visualized the sequence of interest with gel electrophoresis. With this method, we could 
confirm that the gene was present in control littermates and deleted in experimental mice, 
however a limitation with this method is that it does not provide any information on a protein 
level. 
2.5 WESTERN BLOT 
For confirming the loss of the transcription factor we investigated in the first study, we used 
western blot. This method demonstrates, based on size, whether a protein is present or removed 
in a certain tissue or cell population. We tried various commercial antibodies, which in theory 
should bind to the protein we studied. Still, none of these antibodies bound to the target protein 
in a specific manner, although several different protocols were assessed.  
We confirmed that the protein extraction and our western blot technique worked, by visualizing 
Actin, one of the most abundant proteins in eukaryotic cells. Indeed, the western blot confirmed 
that the antibodies for Arid3a bound unspecific. Hence, we targeted the Arid3a locus with 
sequencing and found that a loss of the flanked exon 4, a part of the DNA-binding domain of 
our transcription factor, resulted in an allele out of frame and a non-functioning protein.  
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In study IV however, we successfully could confirm the deletion of APOE, by using an 
antibody that showed correct specificity towards our protein of interest. 
2.6 ENZYME-LINKED IMMUNOSORBENT ASSAY  
Enzyme-linked immunosorbent assay (ELISA) is a highly sensitive method for detection of 
specific proteins. We used this method in all of our studies in order to measure the levels of a 
wide range of antibodies in blood plasma. Besides measuring the levels of immunoglobulins 
in study I, we also measured antibody responses to phosphorylcholine after intraperitoneal 
immunization. In study II, we used ELISA for measuring antibodies against CII and in study 
III we looked at antibodies against MOG protein and MOG79-96 peptide. ELISA could also be 
used for measuring cytokines like IL-10, since it gives a very high accuracy and can detect very 
low levels of proteins. 
2.7 INDUCTION AND EVALUATION OF COLLAGEN-INDUCED ARTHRITIS 
For the induction of experimental arthritis in the mice used in the second study, we injected 
male mice with CII in complete Freund’s adjuvant intradermal at the tail base. 35 days later, 
the mice were given a second injection of CII in incomplete Freund’s adjuvant to boost the 
development of disease. The complete form of the adjuvant contained inactivated 
mycobacteria, whereas the incomplete form lacked the bacterial components and only 
consisted of water in oil-emulsion.  
The adjuvant is designed to continuously release the antigens necessary for stimulating an 
immune response, however the disadvantage is that it causes local irritation and wounds at the 
site of injection. The mycobacteria in the initial injection attracts phagocytic cells to the 
injection site, enhancing the immune reactions. However, due to the previously mentioned side-
effects, the incomplete form of the adjuvant was used for boosting. 
For daily evaluation of the disease development after onset, we used a certain scoring system, 
where each inflamed toe or knuckle was given one point, and swollen ankles or wrists 5 points, 
resulting in a maximum of 60 points per animal. This scoring system is a valuable tool for 
following the disease course, while emphasis should be put on having a blinded evaluator and 
scoring in a consistent manner. 
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2.8 INDUCTION AND EVALUATION OF EXPERIMENTAL AUTOIMMUNE 
ENCEPHALOMYELITIS  
In order to induce EAE during study III, we injected female mice intradermal at the tail base 
with either MOG79-96 peptide or the full-length MOG protein, both in incomplete Freund’s 
adjuvant. To enhance the effect of disease development, we gave the mice an intraperitoneal 
injection of Bordetella pertussis toxin on the same day of MOG administration, and another 
injection two days later. Pertussis toxin is widely used to facilitate the induction of EAE and is 
considered to open up the blood-brain barrier, thereby promoting pathogenic T lymphocytes to 
migrate into the central nervous system 102. Other suggested biological effects of this toxin are 
enhancement of cytokine secretion by T cells and induction of lymphocyte proliferation 102.   
For daily disease evaluation, we used a specific scoring system, created for this autoimmune 
disease model, based on balance, weakness and paralysis of tail and limbs. Similar to the former 
mentioned evaluation of CIA in study II, it is of high importance to be blinded and keep 
consistency when using this scoring system. Additionally, we weighed the mice daily and kept 
track of weight loss, which correlated with disease severity.  
2.9 IRRADIATION AND BONE MARROW TRANSPLANTATION 
Numerous bone marrow transplants were performed in study IV. The recipient mice, belonging 
to an inducible mouse model of atherosclerosis, were irradiated twice with three hours apart, 
in order to deplete their immune system, but preserve their gut flora. They were thereafter 
injected in the tail vein with bone marrow cells from mice deficient in mature or germinal 
center B lymphocytes. This method reconstituted the immune system of the irradiated recipient 
mice, through bone marrow progenitor cells of donor mice. Since the donor mice were deficient 
in mature or germinal center B cells, the same deficiencies were obtained by the recipient mice. 
2.10 CELL ISOLATION FROM AORTA 
In order to investigate and characterize the cell populations present in the mouse aorta in the 
fourth study, we dissected aortas from experimental mice and littermate controls, and digested 
them by using specific enzymes. After a sufficient time of digestion, we stained the single cell 
suspensions with specifically chosen fluorescently labeled markers and acquired them using 
flow cytometry, as previously described. 
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3 RESULTS AND DISCUSSION 
3.1 STUDY I: A ROLE OF THE TRANSCRIPTION FACTOR ARID3A IN MOUSE 
B2 CELL EXPANSION AND PERITONEAL B1A GENERATION 
B1a cells, also named CD5+ B cells, are self-renewing cells, persisting throughout the whole 
adult life 94, producing natural autoantibodies 92, 93. They are derived from the fetal liver, as 
well as the bone marrow in the adult mouse, and are abundant in the peritoneal cavity of 
adults 90, 91. Autoantibodies, reactive to numerous plasma antigens and both surface and 
intracellular structures, are found in healthy individuals and germ-free mice 148. These 
antibodies are multi-reactive, do not undergo affinity maturation, and are believed to be 
involved in several physiological events such as homeostasis, immune regulation, resistance to 
infections and modulation of molecules 14, 15, but are also thought to be involved in autoimmune 
disease like Type 1 diabetes mellitus 190 and SLE 83.  
Antibodies associated with B1 cells can cross-react with self-antigens, leading to autoimmune 
diseases, but B1 lymphocytes are also known to play important protective roles in infectious 
diseases. Nevertheless, B1 cells have shown to be involved in cancer, such as B cell acute 
lymphoblastic leukemia (B-ALL) 153 and chronic lymphoid leukemia (CLL) 90. Currently, there 
exists various B1 deficient strains, however they have defects in other B cell subsets as well, 
such as in the B1b or B2 subsets 181 62, 187. Particularly mice with deletion of IκBNS showed 
interesting effects of being deficient in B1a cells, but still producing low numbers of B1b cells 
181. Thus, we were highly interested in creating a murine model lacking only B1a cells, and 
characterizing the effects of this deficiency. 
The ARID family consists of 15 DNA-binding members, involved in proliferation, 
differentiation and regulation of chromatin accessibility. Some of these ARID family members 
have been shown to be involved in various cancers 32 and in the autoimmune disease SLE 244. 
Arid3a, referred to as Bright in mice, is known to activate transcription of IgH and has been 
proposed to be a proto-oncogene. This protein has previously also been shown to be a key 
transcription factor, critically regulating the B1 versus B2 fate in development of B 
lymphopoiesis 127. Arid3a is known to alter IgH V gene expression 99, 250 , regulate the BCR 
signaling 213, 251 and play important roles in transcriptional activation and cell growth 206. Arid3a 
has been identified as a key target of the microRNA Let-7, highly expressed in the 
hematopoietic system 272. Ectopic expression of Let-7 induced development of B1 cells from 
adult pro-B cells and silencing by knockdown inhibited development of B1 lymphocytes in 
fetal pro-B cells 277.  
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Let-7 and the RNA-binding protein LIN28B have been suggested to play critical roles in 
specifying the B1 versus B2 cell lineage 272. According to the Immunological Genome Project 
(ImmGen) database 98, Arid3a is expressed in B lymphocytes, particularly in the early 
progenitors. We were therefore interested in conditionally deleting the gene encoding for this 
transcription factor and investigating the effects of this on B lymphocyte development and B 
cell subsets, like the B1a subset. 
Deletion of Arid3a has previously been shown to result in embryonic lethality, with less than 
1% of the mice surviving to adulthood 246. These rare survivors showed multiple severe defects 
in both hematopoietic stem cells and erythropoiesis 246. To circumvent embryonal lethality, we 
obtained a conditional allele of Arid3a and assessed the function of ARID3A in early and late 
B cell lymphopoiesis using the Mb1-Cre line to determine any possible developmental defect 
in the B cell lineage due to loss of this transcription factor. In our construct, exon 4, the DNA 
binding domain of Arid3a 99, was flanked by loxp sites. When crossed with the Mb1-Cre line, 
known to be specific for B lymphocytes from early stages and throughout B cell development 
and differentiation 101, exon 4 would be removed by Cre recombinase, resulting in an allele out 
of frame and a non-functioning protein.  
We confirmed deletion of the allele in B cells sorted from both bone marrow and peritoneal 
cavity, characterized various subsets of B lymphocytes and found that the absolute cell 
numbers were affected in almost all B cell subsets in bone marrow and spleen, due to loss of 
this transcription factor. All investigated stages of B2 cells, from early progenitors in the bone 
marrow to late mature stages found in the spleen, were greatly expanded, suggesting a possible 
function for Arid3a in leukemia, for example B-ALL. In the peritoneal cavity, the previously 
mentioned B1a cells were strongly reduced, proposing Arid3a to be important for the 
production of B1a cells or for the migration of B1a cells to the peritoneal cavity.  
Even though we could confirm that the Arid3a allele was deleted both in bone marrow and 
peritoneal cavity by Reverse transcription polymerase chain reaction (RT-PCR), we were not 
able to measure the protein levels of ARID3A via Western blot, although having used several 
diverse antibodies. We hypothesized that this was due to unspecific or no binding of these 
antibodies, nevertheless, we could not rule out that a truncated protein was not produced. 
However, since previous studies have shown that conditional deletion of exon 4 in the highly 
related Arid3b led to loss of the protein 123, we proposed a likewise outcome for our protein. 
Furthermore, following the loss of exon 4, an out-of-frame transcript was detected, encoding 
for a nonsense protein.  
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Retrieving information from the ImmGen database 98, we saw that Arid3a also is expressed in 
granulocytes, particularly neutrophils from the bone marrow, which made us curious to 
interrogate the conditional loss of this allele in this type of immune cells and compare it to the 
effects we saw on B  cells. Thus, we created a lineage-specific deletion of Arid3a, via 
S100A8- Cre, formerly shown to be neutrophil-specific 161, 241. Looking at various different 
immune cells like neutrophils, monocytes and macrophages, we saw no significant effects upon 
loss of this gene, supporting the hypothesis that Arid3a is B lineage specific and important in 
several diverse B cell subsets. In order to further investigate the specificity of Arid3a and 
interrogate a possible implication in disease like cancer, we created an additional Arid3a 
murine model, crossed with Vav1-Cre, previously shown to be specific for hematopoietic stem 
cells 74, 278.  
Analysis of several different B cell subsets in mice lacking Arid3a in the hematopoietic stem 
cells showed no significant differences, indicating no direct function for Arid3a in HSCs and 
early progenitors, in contrast to the previously mentioned study where Arid3a had been 
deleted  246. It is unclear whether the effect they saw upon loss of Arid3a in hematopoietic stem 
cells was dependent on the closely related Arid3b, however conditionally deleting Arid3b 
resulted in unperturbed HSC populations 123, suggesting that HSC development is independent 
of Arid3b. The latter study showed additional results, indicating both ARID3A and ARID3B 
transcription factors to be required for B cell development 123.  
Since Arid3b is closely related to Arid3a 256 and the formerly mentioned study showed that 
both of these transcription factors are important for B cell lymphopoiesis 123, we hypothesized 
that the loss of Arid3a might be compensated by Arid3b. Nevertheless, it has formerly been 
demonstrated that this closely related paralogue, also named Bdp, is not upregulated due to loss 
of Arid3a 246, and thus it is unlikely that paralogous redundancy occurs in our murine model. 
These results together with our previous results suggest important functions for Arid3a in 
B lymphocytes and propose Arid3a to be restricted to the B cell lineage. According to the 
ImmGen database 98, Arid3a is not highly expressed in hematopoietic stem cells of mice, 
however the expression in human hematopoietic stem cells is higher, and thus one should not 
rule out that Arid3a could be important for hematopoietic stem cells of humans. 
A previous study suggests this transcription factor to induce autoimmunity and proposes an 
Arid3a transgenic model that could be used for future analyses of B lymphocyte 
autoreactivity 217. In that study Arid3a was constitutively expressed in all B lineage cells, 
leading to an increased total amount of B cells in the bone marrow, however not in the 
individual subpopulations.  
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The transitional B cell numbers in the spleen were expanded in that murine model, as well as 
the IgG levels in serum. Non-pathogenic autoantibodies against phosphorylcholine (PC) are 
produced by B1 cells and occur naturally. The anti-PC responses in the mentioned study were 
enhanced, however responses to other foreign proteins did not occur. These results from 
overexpression of Arid3a are in concordance with our results after conditionally deleting this 
gene, except the fact that they saw no response to other foreign antigens, since we have seen 
significant differences of antibody levels in serum from our murine model after immunization 
with NP-Keyhole Limpet Hemocyanin (NP-KLH). 
Former studies have revealed that antibodies against PC are anti- inflammatory, playing an 
important protective role in cardiovascular disease (CVD) 69. It has been proposed that IgM 
antibodies against PC could be protection markers for CVD, where low levels of IgM anti-PC 
would be a marker for increased risk of developing CVD 71. These results indicate a possible 
implication for Arid3a in atherosclerosis and CVD, since the levels of antibodies against PC 
were greatly reduced in both naïve and immunized mice in our conditional model.  
An interesting aspect of overexpressing Arid3a was the presence of anti-nuclear antibodies 
(ANAs), used to characterize autoimmune diseases like SLE, in the serum of young transgenic 
mice 217. Another study, with numerous SLE patients involved, correlated dramatically 
increased numbers of Arid3a+ B cells with increased disease activity, suggesting ARID3A as 
a potential marker for B cells correlated SLE 244. These results together with our findings 
highlight the importance of further investigating the function of Arid3a and propose our model 
to be useful for diseases where natural antibodies are implicated. 
 
3.2 STUDY II: GERMINAL CENTER B CELLS ARE ESSENTIAL FOR 
COLLAGEN-INDUCED ARTHRITIS 
Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease, characterized by 
swelling of the joints, persistent synovitis, autoantibodies like rheumatoid factor and anti-
citrullinated protein antibodies (ACPAs), and destruction of the cartilage in the joints, resulting 
in severe disability. RA affects 0.5-1% of the adult population 97, however the etiology of the 
disease is not fully understood. Nevertheless, it is known that both B and T cells are of 
pathogenic importance in the disease 143, which highlights the significance of investigating the 
function and implication of the adaptive immune system in RA.  
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Antibody specificities occurring in collagen- induced arthritis (CIA), a disease model 
commonly used in studies of RA, where rodents develop arthritis after immunization with Type 
II collagen (CII) 50, 236, have been demonstrated in clinical subsets of RA 31, emphasizing the 
relevance of interrogating the disease course of CIA and the implication of antibodies to better 
understand experimental arthritis. B lymphocytes secreting antibodies to CII are found early in 
the disease and IgG has been shown to be the main subtype 182, 229. It has also been demonstrated 
that the B lymphocyte response to CII in RA patients is associated with HLA-DR4, hence 
reflecting a CII-specific activation of T lymphocytes 201, 205. B lymphocytes are known to be of 
high importance for experimental arthritis, however which B cell subset is responsible for 
disease development and progression has been unknown.  
Histological observations in patients with RA have elucidated the presence of germinal centers 
(GCs) in inflamed joints 214, 228, and similar results have been demonstrated in the joints and 
secondary lymphoid tissues of mice 84. Other studies have directly suggested the formation and 
function of GCs as important contributors to RA 257, endorsing the importance of our study. 
However, antigen-collagen antibodies are of a germline configuration. It is not clear what 
function GC formation may perform in the pathogenesis of CIA. 
CIA is a frequently used and accepted disease model of RA, nevertheless there are obvious 
differences between the human disease and the murine model 117, 259. One of these differences 
is the reversed gender susceptibility. While female predominance is characteristic for RA 52, 
the incidence for male mice to develop CIA is greater than for female mice. Studies have 
proposed a protective function of estrogen in female mice 110, yet others have demonstrated 
both anti-inflammatory and pro-inflammatory functions for estrogen 223.  
Why autoimmune disease like RA has a high prevalence in women however, remains unclear 
66, highlighting the complexity of this disease and the immuno-modulating role of estrogen. 
Since most published CIA experiments have been performed on male mice and our aim was to 
investigate the function of B cells and possibly clarify which subset could responsible for 
disease development and progression, we decided to use male mice only.  
The disease is clearly associated to the MHC-region, and therefore we used B6NQ mice 
expressing the H-2q haplotype, previously shown to sufficiently develop disease 226, 260, 261. This 
H-2q haplotype is required for the presentation of the immunodominant T cell epitope from 
collagen. We first verified that the CII we were using functioned as desired and that our models 
were susceptible to CIA. Our results were in agreement with formerly presented data, both the 
disease development and the progression, as well as the antibody titers 226.  
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We subsequently used two different conditional gene knockouts to interrogate the disease 
course of CIA, and to further clarify the function of B cells and antibody secretion in disease. 
These two murine models were deficient in either the mature or the GC subsets of B 
lymphocytes, the latter one important for antibody production.  
In the first murine model, follicular and marginal zone B cells were depleted, as well as memory 
B cells, while the second mouse model lacked only the GC B cell subset. Both models showed 
similar results in cell number and antibody levels compared to wildtype litter mates, since 
transitional B cells develop into follicular B cells and then further into GC B cells. When 
deleting in the GC subset, the mouse will lack only germinal center B lymphocytes, however 
when deleting in the late transitional stages, all subsets that transitional B cells could 
differentiate into will be depleted, including the GC B cell subset. Indeed, our data showed that 
both models lacked GC B cells, as well as had no or very low production of IgG and antibodies 
against Type II collagen.  
These GC-deficient mice had on the other hand normal levels of natural antibodies, since the 
main subset secreting IgM is B1a cells, predominantly found in the peritoneal and pleural 
cavities. The most interesting finding however, was that mice lacking G B lymphocytes were 
fully protected against experimental arthritis, clarifying the role of GC B cells in CIA and 
proposing important functions for GC B cells in RA. Mice that are B cell-deficient and thus 
lacking antibodies have previously been shown to be protected against CIA 226, in line with the 
results we demonstrated in both of our murine models. 
Early treatment of the disease in patients is required to prevent and reduce injury of the joints 
and bone erosion. Currently, several different treatments exist, such as disease-modifying anti-
rheumatic drugs (DMARDs) 176, TNF inhibitors 139 and newer biological treatments like B cell 
depleting agents 16, 219. These therapies slow down disease progression, reduce synovitis and 
systemic inflammation, subsequently relieving joint pain and tenderness. However not all 
patients respond sufficiently to these treatments and sometimes they have serious side effects, 
making the search for newer and more refined therapies important. Various antibody therapies 
targeting B lymphocytes have been demonstrated, such as Rituximab 43, 61, 63, Ofatumumab 177, 
230 and Ocrelizumab 73, 222, which bind to membrane-bound CD20 of B lymphocytes, depleting 
them through various mechanisms like antibody- or complement-dependent cellular toxicity 
and induction of apoptosis. However, pro-B and pre- B cells, as well as plasma cells, do not 
express CD20, and thus anti-CD20 therapies do not prevent regeneration of B cells from 
precursors, nor do they directly interfere with antibody production.  
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Our study demonstrates that germinal center B lymphocytes are essential for experimental 
arthritis and highlights the importance of further investigating this antibody-producing subset 
in autoimmune disease. Although the role of B lymphocytes and the implication of antibodies 
in clinical arthritis is likely to be more complicated, targeting germinal centers in RA could 
help refining existing B lymphocyte depleting therapies or possibly aid in creating newer, more 
defined therapies. 
 
3.3 STUDY III: ANTIGEN-DEPENDENT FUNCTIONS FOR GERMINAL CENTERS 
IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
B lymphocytes are essential for both the adaptive and the humoral immunity, producing 
antibodies to help eliminate foreign pathogens and generating a memory, responsible for an 
accelerated and more specific antibody-mediated immune response upon re-exposure to the 
same pathogen 3, 125. It has also been revealed that B cells contribute to regulation and 
pathogenesis of autoimmune disease like multiple sclerosis (MS) 193, however the underlying 
mechanisms are still under exploration, since B lymphocytes have numerous functions in 
immune responses.  
MS is a demyelinating inflammatory disease, considered to be mediated by T lymphocytes, 
resulting in inflammatory lesions, cell infiltration and axonal damage in the central nervous 
system (CNS). To study the disease course and pathogenesis of autoimmune disease such as 
MS, we adopted a well-studied model of inflammatory brain-demyelinating disorders, referred 
to as Experimental autoimmune encephalomyelitis (EAE) 20, 131, 179. We investigated the 
function of B cells and antibodies in this disease by immunizing mice lacking germinal centers 
(GCs) with either myelin oligodendrocyte glycoprotein (MOG) or MOG79-96 peptide, both 
known to be potent encephalitogens for EAE induction 2. The disease onset and progression 
are in concordance with an important study, where the susceptibility of different MHC classes 
to MOG was investigated using several congenic mouse models and numerous of MOG 
peptides 2. Additionally, others have demonstrated a similar disease course, in agreement with 
what we demonstrated in our EAE studies 26. 
Our results show that the loss of GC B cells alters the disease in an antigen-dependent manner, 
proposing that the GC response could protect as well as promote EAE, highlighting the 
importance of GC formation in disease development and progression. The disease model of 
EAE has both similarities with and differences from the human disease, such as the fact that 
multiple sclerosis affects women three times more than men 47.  
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Likewise, mainly female mice are susceptible to EAE 47, 191. For that reason, we used only 
female mice in our study. Due to that MS and EAE are both considered to be T cell mediated 
diseases 55, we were interested in looking at the T cell subsets and clarify whether those were 
affected in our disease model as well.  
Interestingly, in contrast to former studies 55, we did not see any differences in various T cell 
subsets between experimental mice and littermate controls, except a significant decrease in 
regulatory T cells in the inguinal lymph nodes. Since our conditional mouse model lacked GC 
B cells, and the germinal centers are the key sites of class-switched antibody production 55, the 
production of IgG and antibodies against both MOG protein and MOG79-96 peptide was 
depleted. The levels of natural antibodies however, were almost unchanged, since this subset 
of antibodies are mainly produced by B1 cells, predominantly found in the pleural and 
peritoneal cavities 88, 209. The involvement of B cells in EAE is still under exploration. Some 
studies have suggested B cells to be responsible for disease development 186, while others have 
demonstrated protective roles for B cells 264.  
Additionally, other groups have demonstrated that the roles of B cells in EAE is subset-
dependent 140, 141. We showed, with the help of a germinal center-deficient mouse model, that 
GC B cells can both be pathogenic and protective, depending on antigen used for induction. 
This suggests a regulatory role for B cells in EAE, in agreement with previous studies 68, 141. 
The mechanisms behind these findings remain unknown and need to be further investigated, 
however it is likely that antibodies are involved, since the GCs are responsible for production 
of IgG and other class-switched antibodies. Oligoclonal IgG is common in MS patients 29, 115, 
and levels of IgG in central spinal fluid can be directly correlated to disease progression 255.  
We could propose that disease progression might be independent of antibodies, since B cell-
depleting therapies result in improvement of autoimmune disease. It has been shown in both 
mouse and man that B lymphocytes secrete elevated levels of the pro-inflammatory cytokine 
IL-6 during disease, and that IL-6 deficiency results in less severe disease 18. Nevertheless, our 
findings demonstrate that it is improbable that the disease course is independent of antibodies, 
and more likely that the mechanisms are highly complex. 
Whether EAE is a good model for studying MS is controversial. While EAE is the most 
commonly used disease model for human inflammatory demyelinating disease 2, 47  , others 
propose that this disease model is unlikely to be a useful model for demyelinating disease, but 
rather a model for human acute disseminated encephalomyelitis or acute hemorrhagic 
leukoencephalitis 21.  
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EAE resembles the symptoms and pathology of MS in several ways, and although this animal 
model differs from the human disease in many aspects, much of our understanding regarding 
the inflammatory and autoimmune mechanisms is due to this disease model. At present, several 
different therapeutics for treating MS exists, like general lymphocyte-depleting therapies 109, 
more specific B cell-depleting therapies 89 and monoclonal antibodies targeting certain 
structures found on certain cell types 25. Several MS therapies have been tested on the EAE 
disease model 196, highlighting its validity as a model for MS and for developing more refined 
treatments. 
 
3.4 STUDY IV: ACUTE LOSS OF APOLIPOPROTEIN E TRIGGERS AN AUTOIMMUNE 
RESPONSE THAT ACCELERATES ATHEROSCLEROSIS 
Atherosclerosis is a chronic inflammatory disorder, where both cells of the immune system and 
cells of the vessel walls are involved. Atherosclerosis is the underlying cause of most 
cardiovascular diseases (CVD), leading to stroke and myocardial infarctions 86. The 
atherogenic process affects both the innate and adaptive arms of immunity, often activated due 
to hyperlipidemia, and resulting in the development of atherosclerotic plaques that can trigger 
the formation of occlusive thrombi 13, 77, 204.  
Except pro-inflammatory lipoproteins and hemodynamics of the blood flow in the arteries, an 
important factor that can influence atherogenesis is, heritability 212. GWAS have identified 58 
regions in the genome, where SNPs are associated with increased risk of developing coronary 
artery disease 46, 163. Since atherosclerosis is a leading cause of CVD worldwide, we were 
interested in investigating this disorder and possible risk factors with the help of a novel 
atherosclerotic mouse model. Numerous animal models for studying atherogenesis exist, 
however none of these are ideal, due to limitations in disease development and large differences 
from the human disorder like heart rate, total plasma cholesterol, sites of atherosclerosis 
development and the time to develop atherosclerotic lesions 76.  
Most importantly, humans develop atherosclerosis in the adult stage of life, yet the most 
frequently used mouse models of atherosclerosis, Apoe -/- or Ldlr -/- 262, are deletions of genes 
during early embryogenesis 220, 266.  Therefore we aimed at creating an inducible atherogenic 
mouse model, which we could use for studying the early immune responses and the 
development of atherosclerotic plaques, better resembling events in the human disease before 
and at disease onset.  
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Our findings showed that inducing deletion of Apoe in the adult stage of the mouse triggers 
autoimmune responses, resulting in acute hypercholesterolemia and accelerating the formation 
of atherosclerotic lesions. We could verify the loss of apolipoprotein E and showed that the 
cholesterol levels raised significantly in our experimental group, compared to the littermate 
controls, just a few days after gene deletion. The cholesterol levels continued to raise and 140 
days after disease induction, the levels were almost 4-fold higher in experimental mice, than in 
the control group, in contrast to the triglyceride levels, which remained unaltered between the 
groups.  
We also quantified atherosclerotic lesions in the aortas and demonstrated that acute loss of 
Apoe resulted in development of plaques in experimental mice, while littermate controls 
developed none. These results are in agreement with previously revealed data, where Apoe-
deficient transgenic mice demonstrated severe hypercholesterolemia and developed 
atherosclerotic lesions, similar to those in humans 157. It is known that B cells are implicated in 
the development of atherosclerosis, however the underlying mechanisms of atheromodulation 
is still unexplored. We further investigated the spleen and lymph nodes, as well as digested 
aortas for analysis, in our inducible mouse model, and found no differences in the transitional, 
follicular or marginal zone B cell subsets, neither did we see any general cell expansions of B 
cells, T cells and myeloid subsets upon acute loss of Apoe.  
Looking at the T helper cells and regulatory T cells, we could confirm an increase in the 
experimental mice, but one of the most interesting findings was the large increase in cell 
numbers of germinal center (GC) B cells, the subset which is responsible for producing class-
switched antibodies, early after the deletion of Apoe. These results are in accordance with 
findings reported in a previous study that proposes a role for regulatory T cells in controlling 
the germinal center reaction in peripheral lymphoid organs and a pro-atherogenic function for 
germinal centers 40. 
In line with already mentioned results, we saw increased levels the cytokine interferon gamma 
(IFN-γ), known to be pro-atherogenic 253, as well as increased levels of IL-4 and IL-10. The 
signaling of the cytokine IL-4 has previously been shown to have regulatory functions in 
atherogenesis and has in the same study been suggested to have therapeutic potential in 
CVD 130. In contrary, IL- 10 has in several studies been demonstrated to have protective 
functions in atherosclerosis 85, 137, 188, 224. However, conflicting results claim that IL-10 does not 
alter atherosclerosis in mice 207, declaring that regulation and modulation of this disease is 
highly complex.  
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After 70 days on a high fat-diet, the amount of plasma cells were significantly higher in the 
experimental group, as well as the levels of antibodies compared to the control group, 
indicating that hypercholesterolemia induced a systemic inflammatory response. To investigate 
the role of the spleen in atherosclerosis, we performed splenectomy on our experimental mice 
and compared them with sham-operated mice. Interestingly, we saw a decrease of the B1a cells 
in the peritoneal cavity of splenectomized mice, as well as a decrease in IgM, since B1a cells 
are the main subset for producing natural antibodies.  
In contrast to B2 cells, which are considered to be atherogenic 4, B1a cells have in former 
studies been shown to have atheroprotective functions 33, due to the secretion of natural IgM 
antibodies which clear modified low-density lipoprotein, as well as necrotic and apoptotic  
debris 124. In the same study, B1a cells were suggested to act as regulatory B cells by the 
secretion of the anti-inflammatory cytokine IL-10, inhibiting pro-inflammatory cytokines, 
produced by T cells and macrophages in atherosclerotic lesions. Additionally, others have 
demonstrated B1b cells to produce atheroprotective IgM antibodies against oxidation-specific 
epitopes in mice, and proposed a similar mechanism in humans 202.  
To further interrogate our findings regarding germinal center formation, and clarify a possible 
function of germinal centers in atherosclerosis, we performed numerous bone marrow 
transplants from mice deficient in developing either mature B cells or GC B cells, into 
irradiated mice of our inducible Apoe knockout model. We showed that the loss of mature B 
cells led to a significant decrease of atherosclerotic lesions in the aorta of experimental mice. 
Interestingly, we saw a large decrease of atherosclerotic plaques in mice that lacked GCs, 
proposing the GC reaction to be responsible for pro-atherosclerotic autoimmune responses. 
Former studies have demonstrated atheroprotective roles for B cell-responses in the spleen 78, 
yet other have proposed GC formation as pro-atherogenic 40. The involvement and function of 
B cells in atherosclerosis and CVD is likely to be B cell subset-dependent 59, 184. Our findings, 
supported by previously published data from others, 33 suggest an opportunity to inhibit or 
reduce atherosclerosis by targeting and dampening the GC-response. This knowledge aid 
development of future treatments for atherosclerosis and cardiovascular disease. 
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4 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
The studies in this thesis have aimed at identifying and understanding the involvement of the 
adaptive immune system and B cells in various autoimmune disorders, by using different 
genetically modified mouse models. We created and characterized several new murine models, 
which could be used for future studies as well. We also investigated inducible disease models 
like EAE and CIA in order to investigate disease course and development. The knowledge 
gained and the data provided from our studies can be applicable both in future research project, 
and possibly when developing or refining therapies for autoimmune disorders. The conditional 
allele of Arid3a that we created to interrogate its function regarding B1 and B2 cell fate, has 
improved our understanding of the transcription factor ARID3A in early and late 
B lymphopoiesis.  
This model did not lack B1 cells, however it had reduced B1a cell numbers in the peritoneal 
cavity, reduced B1 cells in the bone marrow and expanded numbers of cells in most 
B2 cell subsets in both bone marrow and spleen, as well as reduced levels of several antibodies 
in blood plasma, especially those against phosphorylcholine. These findings could be useful in 
investigating and understanding disease models where natural antibodies are involved, such as 
SLE 244. In a future project, it would be of value to study B cell progenitors in the fetal liver of 
this conditional knockout, since Arid3a is highly expressed in this organ according to the 
ImmGen database 98. There is a possibility that ARID3A and ARID3B have redundant 
functions in B lymphopoiesis, hence it could be of interest in setting up a combined deletion of 
these transcription factors in order to clarify this. 
In the second and third study, we applied well-established and accepted disease models of 
rheumatoid arthritis and multiple sclerosis on two different germinal center deficient strains, 
and found that the GC reaction can both prevent and promote disease. When inducing CIA, an 
animal model of RA, in GC deficient mice, we demonstrated that these mice were entirely 
protected against disease, although they were completely susceptible to CIA. Investigating the 
disease course of EAE, a rodent model used for studying MS, we found that germinal center 
B cells were either disease promoting or protecting, in an antigen-dependent manner. In both 
of these studies, the importance of GCs were elucidated, highlighting the significance of 
interrogating this B cell subset in future projects. 
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For forthcoming studies, it could be valuable to inject B cells or antibodies like IgG, in GC 
deficient mice induced with CIA or EAE, in order to explore and evaluate the disease outcome. 
It would be interesting to see if the protective function of GC B cells in CIA is abolished after 
the injection of either B cells or antibodies, and if the effects we saw in the EAE model could 
be altered. Regarding the GC reaction in general, it could be of interested to study this 
B cell subset in humans, and possibly target it for more refined therapies, compared to the 
treatments that currently exist.  
The inducible model of hypercholesterolemia and atherosclerosis provide us with a new disease 
model that can be used for investigating the involvement of the immune system and the 
development of atherosclerotic lesions in the adult mouse. Our characterization of this mouse 
model confirmed that GCs and antibodies play significant roles in several disorders, and that 
targeting this subset in a clinical setting could be of great interest. We have used several 
advanced methods for characterizing our animal models, as well as for evaluating the effects 
of disease induction.  
It can be challenging to perform research on murine models resembling disease in humans, due 
to several genetic and physiological differences 183, however animal models are a valuable 
resource for the studies of autoimmune disease and are more similar to human disorders than 
can be expected 183. The findings described in this thesis do not only demonstrate how murine 
models can be utilized to learn more about immunology and inflammation under various 
settings, but also contribute significantly to the field of adaptive immunity and autoimmune 
disease. 
 
 
 
 
 
 
 
 
 42 
5 ACKNOWLEDGEMENTS 
During my years at Karolinska Institutet, I have been surrounded by many intelligent and 
talented people. There are many people I would like to thank: 
My main supervisor Dr. Stephen Malin. Without you, this thesis would not have been possible. 
Thank you for believing in me, supporting me and teaching me everything about immunology 
and B cells. I’m thankful for our meetings, our discussions and for giving me the opportunity 
to be a part of your research group. My co-supervisor Professor Gunilla Karlsson Hedestam. 
Thank you for your support, for our inspiring discussions, and for your inputs and great ideas. 
My co-supervisor Professor Dan Grandér. Thank you for sharing your experience in science 
with me and for our nice talks at the gym. You were a very humble person, a great scientist, 
and we all miss you. 
Professor Göran Hansson, thank you for many wonderful and interesting years in your lab 
and for all nice talks about our roots in Tornedalen. Thank you John, Andres, Anton, Yajuan 
and everyone else in the Hansson group for our friendship and for many amazing years 
together. Thank you Ingrid, you are a lovely and humble person. Thank you Ann for all your 
support, you are an amazing person. Many thanks to beloved Eva, you are wonderful. To 
Aleem, Marita, Belghis and everyone else at CMM floor 3 for our interesting talks and 
discussions. Many thanks to Professor Per Eriksson and all current and past members of the 
whole unit which I have had the pleasure to get to know over the years. Thank you Professor 
Tomas Olsson for our nice collaboration and for being a humble person. To every kind soul in 
the whole Olsson group, thank you for being wonderful people. Special thanks to André, for 
always being helpful and for being a lovely person. Thanks to everyone at CMM floor 4, for 
being nice and friendly, both in private and at work. Thanks to Timmy and Ingela for our nice 
and interesting talks. Many thanks to everyone at CMM floor 5.  
The CyAn. We have spent endless days and nights together. Keep going strong, I believe in 
you. You will always have a special place in my heart. Many thanks to Annika for rescuing 
my experiments, for answering e-mails during night time and for being an amazing person.  
Many thanks to Professor Rickard Holmdahl for our collaboration and to everyone else at 
MIR. Carlos and Kristina, you are lovely people and I will miss you a lot. Many thanks to 
Sandra, Michelle, Anna-Lena, Rebecca, Selam, Joline and everyone else at AKM for being 
wonderful and caring people.  
Special thanks to the mice. Without you, none of these projects would have been possible.  
  43 
Thank you Karolinska Institutet, for giving me the opportunity to become a scientist. 
Hovsep, thank you for all your support when I was new at CMM and after. For sharing your 
knowledge and friendship with me. You are one of the most helpful people I have ever met. 
Words can not describe how thankful I am. Thank you my beloved Mona, you are like a sister 
to me. You are a lovely person, an intelligent scientist and an amazing friend. Thank you my 
dear Albert, you are like a brother to me. We have shared endless time in the lab and I am 
thankful for all your help and support, both in science and in life. Thank you Daniel J, for our 
friendship, support and for the fun time we have had together. Thank you Kajsa, for your 
friendship, knowledge and for sharing your experience in science with me. 
Micke, we have known each other for decades, and you are my best friend. You are an amazing 
person, and although we live far apart today, I always keep you close to my heart. Danne and 
Ingemar, you are wonderful, with warm hearts and kind souls. Nacima, you are my sister, 
even if we don’t share biology. You are an amazing person and a wonderful friend. Thank you 
for always supporting and caring for me. يتخأ كبحأ 
Most of all, I would like to thank my family. My love to you all is endless.  
I am endlessly grateful to my parents, for everything. For showing me the way in life, sharing 
your experiences with me and being the best parents one could ever have. You are my parents, 
but also my best friends, and words can not describe how much I love you. 
My beloved mother Tilla, я тебя люблю. You made me the person I am today. You raised me 
and you have always cared for me and been there for me. You know who I am, how I think and 
what I feel. When I was a child, you introduced me to the world of gym, sports and dancing, 
and decades later, we still dance and exercise together. We have traveled all over the world 
together, you and me. You showed me history and culture, the sun and the sea. Thank you for 
believing in me, supporting me and helping with everything. You are an amazing mother, you 
are super-woman. 
My wonderful father Tore, minä rakastan sinua. Thank you for teaching me everything and 
for always being very enthusiastic. For all the knowledge you have shared with me, for teaching 
me how to read, write, count, ride a bicycle. From every name of the trees and flowers in the 
forest, to every calculation in mathematics and every chemical in chemistry. You taught me 
everything, and you always believed in me. For the times we went camping and fishing 
together, and for teaching me about motorcycles and cars. You are an amazing father, you are 
fader-konungen.  
 44 
I would like to thank my love Shahin. Thank you for every time we have laughed together and 
for every time you pushed me to stay strong. For your experience and knowledge in science 
and for all the help and support, when my experiments did not seem to have an end. For every 
hour you spent with me in the lab and every time you picked me up in the night after late 
experiments. I haven’t forgotten every single time you showed up from nowhere with food, 
when you knew I would stay all night at work. Thank you for every calculation and analysis 
you have helped me with and for every sample you have plated together with me. For every 
time we walk in the forest with the dogs, every journey around the world, and every hour 
together in the gym. Words can not describe how thankful I am, my love. تقشاع نم متسه  
My mother, father and sister in law, Mojdeh, Ebrahim and Shabnam, and all the family, 
thank you for always being sweet and caring. 
My sister Christine and her husband Christoph, and their children Arthur and Sophie. My 
brother Roland and his wife Catarina, and their children Nikolai and David. My brother 
Anton and his wife Anette and their daughter Joline. My brother Melker and his family Sissel, 
Linn-Malin and Wilhelm in Norway. Thank you for being a part of my life and sharing many 
happy moments with me.  
My wonderful uncle Iza and his lovely wife Rita, and my beloved cousins Sima and Juliya. 
Thank you for being amazing. I miss you so much. םכתוא תבהוא ינא 
To all my relatives in Odessa, Tornedalen and all over the world, I keep you all close to my 
heart. 
Thank you Hayati for filling my life with dance, love and happiness. You have given me a 
second family, which I love deeply. Without you, my life wouldn’t be complete.  
They say a dog is a man’s best friend, I am blessed with two. Devi and Apollo, for always 
being there for me, always being happy and helping me to stay strong. Thank you for every 
moment we share together, you are the best support one could ever have, and my love for you 
both is endless.  
  45 
6 REFERENCES 
1 Abul K. Abbas, Andrew H. Lichtman, and Shiv Pillai, Cellular and Molecular 
Immunology [Elektronisk Resurs] (Philadelphia, PA: Elsevier Saunders, 2015). 
2 K. B. Abdul-Majid, J. Jirholt, C. Stadelmann, A. Stefferl, P. Kjellen, E. Wallstrom, R. 
Holmdahl, H. Lassmann, T. Olsson, and R. A. Harris, 'Screening of Several H-2 
Congenic Mouse Strains Identified H-2(Q) Mice as Highly Susceptible to Mog-
Induced Eae with Minimal Adjuvant Requirement', J Neuroimmunol, 111 (2000), 23-
33. 
3 I. Airoldi, L. Raffaghello, C. Cocco, R. Guglielmino, S. Roncella, F. Fedeli, C. 
Gambini, and V. Pistoia, 'Heterogeneous Expression of Interleukin-18 and Its Receptor 
in B-Cell Lymphoproliferative Disorders Deriving from Naive, Germinal Center, and 
Memory B Lymphocytes', Clin Cancer Res, 10 (2004), 144-54. 
4 H. Ait-Oufella, O. Herbin, J. D. Bouaziz, C. J. Binder, C. Uyttenhove, L. Laurans, S. 
Taleb, E. Van Vre, B. Esposito, J. Vilar, J. Sirvent, J. Van Snick, A. Tedgui, T. F. 
Tedder, and Z. Mallat, 'B Cell Depletion Reduces the Development of Atherosclerosis 
in Mice', J Exp Med, 207 (2010), 1579-87. 
5 K. Akashi, M. Kondo, S. Cheshier, J. Shizuru, K. Gandy, J. Domen, R. Mebius, D. 
Traver, and I. L. Weissman, 'Lymphoid Development from Stem Cells and the 
Common Lymphocyte Progenitors', Cold Spring Harb Symp Quant Biol, 64 (1999), 1-
12. 
6 S. Akira, S. Uematsu, and O. Takeuchi, 'Pathogen Recognition and Innate Immunity', 
Cell, 124 (2006), 783-801. 
7 Bruce Alberts, Molecular Biology of the Cell (New York: Garland Science, 2002). 
8 D. Allman, R. C. Lindsley, W. DeMuth, K. Rudd, S. A. Shinton, and R. R. Hardy, 
'Resolution of Three Nonproliferative Immature Splenic B Cell Subsets Reveals 
Multiple Selection Points During Peripheral B Cell Maturation', J Immunol, 167 (2001), 
6834-40. 
9 D. M. Allman, S. E. Ferguson, and M. P. Cancro, 'Peripheral B Cell Maturation. I. 
Immature Peripheral B Cells in Adults Are Heat-Stable Antigenhi and Exhibit Unique 
Signaling Characteristics', J Immunol, 149 (1992), 2533-40. 
10 D. M. Allman, S. E. Ferguson, V. M. Lentz, and M. P. Cancro, 'Peripheral B Cell 
Maturation. Ii. Heat-Stable Antigen(Hi) Splenic B Cells Are an Immature 
Developmental Intermediate in the Production of Long-Lived Marrow-Derived B 
Cells', J Immunol, 151 (1993), 4431-44. 
11 S. Amu, S. P. Saunders, M. Kronenberg, N. E. Mangan, A. Atzberger, and P. G. Fallon, 
'Regulatory B Cells Prevent and Reverse Allergic Airway Inflammation Via Foxp3-
Positive T Regulatory Cells in a Murine Model', J Allergy Clin Immunol, 125 (2010), 
1114-24 e8. 
 46 
12 G. An, C. A. Miner, J. C. Nixon, P. W. Kincade, J. Bryant, P. W. Tucker, and C. F. 
Webb, 'Loss of Bright/Arid3a Function Promotes Developmental Plasticity', Stem 
Cells, 28 (2010), 1560-7. 
13 J. Andersson, P. Libby, and G. K. Hansson, 'Adaptive Immunity and Atherosclerosis', 
Clin Immunol, 134 (2010), 33-46. 
14 S. Avrameas, 'Natural Autoantibodies: From 'Horror Autotoxicus' to 'Gnothi Seauton'', 
Immunol Today, 12 (1991), 154-9. 
15 S. Avrameas, and T. Ternynck, 'The Natural Autoantibodies System: Between 
Hypotheses and Facts', Mol Immunol, 30 (1993), 1133-42. 
16 A. Bagust, A. Boland, J. Hockenhull, N. Fleeman, J. Greenhalgh, Y. Dundar, C. 
Proudlove, T. Kennedy, R. Moots, P. Williamson, and R. Dickson, 'Rituximab for the 
Treatment of Rheumatoid Arthritis', Health Technol Assess, 13 Suppl 2 (2009), 23-9. 
17 H. Bammer, G. Schaltenbrand, and H. Solcher, '[Examinations of Twins in Multiple 
Sclerosis]', Dtsch Z Nervenheilkd, 181 (1960), 261-79. 
18 T. A. Barr, P. Shen, S. Brown, V. Lampropoulou, T. Roch, S. Lawrie, B. Fan, R. A. 
O'Connor, S. M. Anderton, A. Bar-Or, S. Fillatreau, and D. Gray, 'B Cell Depletion 
Therapy Ameliorates Autoimmune Disease through Ablation of Il-6-Producing B 
Cells', J Exp Med, 209 (2012), 1001-10. 
19 K. Bauer, X. Yu, P. Wernhoff, D. Koczan, H. J. Thiesen, and S. M. Ibrahim, 
'Identification of New Quantitative Trait Loci in Mice with Collagen-Induced Arthritis', 
Arthritis Rheum, 50 (2004), 3721-8. 
20 A. G. Baxter, 'The Origin and Application of Experimental Autoimmune 
Encephalomyelitis', Nat Rev Immunol, 7 (2007), 904-12. 
21 P. O. Behan, and A. Chaudhuri, 'Eae Is Not a Useful Model for Demyelinating Disease', 
Mult Scler Relat Disord, 3 (2014), 565-74. 
22 L. Belbasis, V. Bellou, E. Evangelou, J. P. Ioannidis, and I. Tzoulaki, 'Environmental 
Risk Factors and Multiple Sclerosis: An Umbrella Review of Systematic Reviews and 
Meta-Analyses', Lancet Neurol, 14 (2015), 263-73. 
23 J. F. Bentzon, and E. Falk, 'Atherosclerotic Lesions in Mouse and Man: Is It the Same 
Disease?', Curr Opin Lipidol, 21 (2010), 434-40. 
24 P. Bhargava, and E. M. Mowry, 'Gut Microbiome and Multiple Sclerosis', Curr Neurol 
Neurosci Rep, 14 (2014), 492. 
25 B. Bielekova, T. Howard, A. N. Packer, N. Richert, G. Blevins, J. Ohayon, T. A. 
Waldmann, H. F. McFarland, and R. Martin, 'Effect of Anti-Cd25 Antibody 
  47 
Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression 
in Multiple Sclerosis', Arch Neurol, 66 (2009), 483-9. 
26 S. Bittner, A. M. Afzali, H. Wiendl, and S. G. Meuth, 'Myelin Oligodendrocyte 
Glycoprotein (Mog35-55) Induced Experimental Autoimmune Encephalomyelitis 
(Eae) in C57bl/6 Mice', J Vis Exp (2014). 
27 P. A. Blair, K. A. Chavez-Rueda, J. G. Evans, M. J. Shlomchik, A. Eddaoudi, D. A. 
Isenberg, M. R. Ehrenstein, and C. Mauri, 'Selective Targeting of B Cells with 
Agonistic Anti-Cd40 Is an Efficacious Strategy for the Generation of Induced 
Regulatory T2-Like B Cells and for the Suppression of Lupus in Mrl/Lpr Mice', J 
Immunol, 182 (2009), 3492-502. 
28 C. Boiers, J. Carrelha, M. Lutteropp, S. Luc, J. C. Green, E. Azzoni, P. S. Woll, A. J. 
Mead, A. Hultquist, G. Swiers, E. G. Perdiguero, I. C. Macaulay, L. Melchiori, T. C. 
Luis, S. Kharazi, T. Bouriez-Jones, Q. Deng, A. Ponten, D. Atkinson, C. T. Jensen, E. 
Sitnicka, F. Geissmann, I. Godin, R. Sandberg, M. F. de Bruijn, and S. E. Jacobsen, 
'Lymphomyeloid Contribution of an Immune-Restricted Progenitor Emerging Prior to 
Definitive Hematopoietic Stem Cells', Cell Stem Cell, 13 (2013), 535-48. 
29 F. Bollengier, P. Delmotte, and A. Lowenthal, 'Biochemical Findings in Multiple 
Sclerosis. Iii. Immunoglobulins of Restricted Heterogeneity and Light Chain 
Distribution in Cerebrospinal Fluid of Patients with Multiple Sclerosis', J Neurol, 212 
(1976), 151-8. 
30 L. Borghesi, J. Aites, S. Nelson, P. Lefterov, P. James, and R. Gerstein, 'E47 Is 
Required for V(D)J Recombinase Activity in Common Lymphoid Progenitors', J Exp 
Med, 202 (2005), 1669-77. 
31 H. Burkhardt, T. Koller, A. Engstrom, K. S. Nandakumar, J. Turnay, H. G. Kraetsch, 
J. R. Kalden, and R. Holmdahl, 'Epitope-Specific Recognition of Type Ii Collagen by 
Rheumatoid Arthritis Antibodies Is Shared with Recognition by Antibodies That Are 
Arthritogenic in Collagen-Induced Arthritis in the Mouse', Arthritis Rheum, 46 (2002), 
2339-48. 
32 T. Cajuso, U. A. Hanninen, J. Kondelin, A. E. Gylfe, T. Tanskanen, R. Katainen, E. 
Pitkanen, H. Ristolainen, E. Kaasinen, M. Taipale, J. Taipale, J. Bohm, L. Renkonen-
Sinisalo, J. P. Mecklin, H. Jarvinen, S. Tuupanen, O. Kilpivaara, and P. Vahteristo, 
'Exome Sequencing Reveals Frequent Inactivating Mutations in Arid1a, Arid1b, Arid2 
and Arid4a in Microsatellite Unstable Colorectal Cancer', Int J Cancer, 135 (2014), 
611-23. 
33 G. Caligiuri, A. Nicoletti, B. Poirier, and G. K. Hansson, 'Protective Immunity against 
Atherosclerosis Carried by B Cells of Hypercholesterolemic Mice', J Clin Invest, 109 
(2002), 745-53. 
34 R. Carsetti, G. Kohler, and M. C. Lamers, 'Transitional B Cells Are the Target of 
Negative Selection in the B Cell Compartment', J Exp Med, 181 (1995), 2129-40. 
 48 
35 A. I. Catrina, A. J. Ytterberg, G. Reynisdottir, V. Malmstrom, and L. Klareskog, 'Lungs, 
Joints and Immunity against Citrullinated Proteins in Rheumatoid Arthritis', Nat Rev 
Rheumatol, 10 (2014), 645-53. 
36 A. Cerutti, M. Cols, and I. Puga, 'Marginal Zone B Cells: Virtues of Innate-Like 
Antibody-Producing Lymphocytes', Nat Rev Immunol, 13 (2013), 118-32. 
37 J. B. Chung, M. Silverman, and J. G. Monroe, 'Transitional B Cells: Step by Step 
Towards Immune Competence', Trends Immunol, 24 (2003), 343-9. 
38 M. R. Clark, M. Mandal, K. Ochiai, and H. Singh, 'Orchestrating B Cell Lymphopoiesis 
through Interplay of Il-7 Receptor and Pre-B Cell Receptor Signalling', Nat Rev 
Immunol, 14 (2014), 69-80. 
39 F. Clas, and M. Loos, 'Antibody-Independent Killing of Gram-Negative Bacteria Via 
the Classical Pathway', Behring Inst Mitt (1984), 59-74. 
40 M. Clement, K. Guedj, F. Andreata, M. Morvan, L. Bey, J. Khallou-Laschet, A. T. 
Gaston, S. Delbosc, J. M. Alsac, P. Bruneval, C. Deschildre, M. Le Borgne, Y. Castier, 
H. J. Kim, H. Cantor, J. B. Michel, G. Caligiuri, and A. Nicoletti, 'Control of the T 
Follicular Helper-Germinal Center B-Cell Axis by Cd8(+) Regulatory T Cells Limits 
Atherosclerosis and Tertiary Lymphoid Organ Development', Circulation, 131 (2015), 
560-70. 
41 C. Cobaleda, A. Schebesta, A. Delogu, and M. Busslinger, 'Pax5: The Guardian of B 
Cell Identity and Function', Nat Immunol, 8 (2007), 463-70. 
42 D. Coenen, P. Verschueren, R. Westhovens, and X. Bossuyt, 'Technical and Diagnostic 
Performance of 6 Assays for the Measurement of Citrullinated Protein/Peptide 
Antibodies in the Diagnosis of Rheumatoid Arthritis', Clin Chem, 53 (2007), 498-504. 
43 S. B. Cohen, P. Emery, M. W. Greenwald, M. Dougados, R. A. Furie, M. C. Genovese, 
E. C. Keystone, J. E. Loveless, G. R. Burmester, M. W. Cravets, E. W. Hessey, T. 
Shaw, M. C. Totoritis, and Reflex Trial Group, 'Rituximab for Rheumatoid Arthritis 
Refractory to Anti-Tumor Necrosis Factor Therapy: Results of a Multicenter, 
Randomized, Double-Blind, Placebo-Controlled, Phase Iii Trial Evaluating Primary 
Efficacy and Safety at Twenty-Four Weeks', Arthritis Rheum, 54 (2006), 2793-806. 
44 P. Concannon, S. S. Rich, and G. T. Nepom, 'Genetics of Type 1a Diabetes', N Engl J 
Med, 360 (2009), 1646-54. 
45 J. Condon, J. E. Shaw, M. Luciano, K. O. Kyvik, N. G. Martin, and D. L. Duffy, 'A 
Study of Diabetes Mellitus within a Large Sample of Australian Twins', Twin Res Hum 
Genet, 11 (2008), 28-40. 
46 C. ARDIoGRAMplusC4D Consortium, P. Deloukas, S. Kanoni, C. Willenborg, M. 
Farrall, T. L. Assimes, J. R. Thompson, E. Ingelsson, D. Saleheen, J. Erdmann, B. A. 
Goldstein, K. Stirrups, I. R. Konig, J. B. Cazier, A. Johansson, A. S. Hall, J. Y. Lee, C. 
J. Willer, J. C. Chambers, T. Esko, L. Folkersen, A. Goel, E. Grundberg, A. S. 
  49 
Havulinna, W. K. Ho, J. C. Hopewell, N. Eriksson, M. E. Kleber, K. Kristiansson, P. 
Lundmark, L. P. Lyytikainen, S. Rafelt, D. Shungin, R. J. Strawbridge, G. Thorleifsson, 
E. Tikkanen, N. Van Zuydam, B. F. Voight, L. L. Waite, W. Zhang, A. Ziegler, D. 
Absher, D. Altshuler, A. J. Balmforth, I. Barroso, P. S. Braund, C. Burgdorf, S. Claudi-
Boehm, D. Cox, M. Dimitriou, R. Do, Diagram Consortium, Cardiogenics Consortium, 
A. S. Doney, N. El Mokhtari, P. Eriksson, K. Fischer, P. Fontanillas, A. Franco-
Cereceda, B. Gigante, L. Groop, S. Gustafsson, J. Hager, G. Hallmans, B. G. Han, S. 
E. Hunt, H. M. Kang, T. Illig, T. Kessler, J. W. Knowles, G. Kolovou, J. Kuusisto, C. 
Langenberg, C. Langford, K. Leander, M. L. Lokki, A. Lundmark, M. I. McCarthy, C. 
Meisinger, O. Melander, E. Mihailov, S. Maouche, A. D. Morris, M. Muller-Nurasyid, 
Ther Consortium Mu, K. Nikus, J. F. Peden, N. W. Rayner, A. Rasheed, S. Rosinger, 
D. Rubin, M. P. Rumpf, A. Schafer, M. Sivananthan, C. Song, A. F. Stewart, S. T. Tan, 
G. Thorgeirsson, C. E. van der Schoot, P. J. Wagner, Consortium Wellcome Trust Case 
Control, G. A. Wells, P. S. Wild, T. P. Yang, P. Amouyel, D. Arveiler, H. Basart, M. 
Boehnke, E. Boerwinkle, P. Brambilla, F. Cambien, A. L. Cupples, U. de Faire, A. 
Dehghan, P. Diemert, S. E. Epstein, A. Evans, M. M. Ferrario, J. Ferrieres, D. Gauguier, 
A. S. Go, A. H. Goodall, V. Gudnason, S. L. Hazen, H. Holm, C. Iribarren, Y. Jang, M. 
Kahonen, F. Kee, H. S. Kim, N. Klopp, W. Koenig, W. Kratzer, K. Kuulasmaa, M. 
Laakso, R. Laaksonen, J. Y. Lee, L. Lind, W. H. Ouwehand, S. Parish, J. E. Park, N. 
L. Pedersen, A. Peters, T. Quertermous, D. J. Rader, V. Salomaa, E. Schadt, S. H. Shah, 
J. Sinisalo, K. Stark, K. Stefansson, D. A. Tregouet, J. Virtamo, L. Wallentin, N. 
Wareham, M. E. Zimmermann, M. S. Nieminen, C. Hengstenberg, M. S. Sandhu, T. 
Pastinen, A. C. Syvanen, G. K. Hovingh, G. Dedoussis, P. W. Franks, T. Lehtimaki, A. 
Metspalu, P. A. Zalloua, A. Siegbahn, S. Schreiber, S. Ripatti, S. S. Blankenberg, M. 
Perola, R. Clarke, B. O. Boehm, C. O'Donnell, M. P. Reilly, W. Marz, R. Collins, S. 
Kathiresan, A. Hamsten, J. S. Kooner, U. Thorsteinsdottir, J. Danesh, C. N. Palmer, R. 
Roberts, H. Watkins, H. Schunkert, and N. J. Samani, 'Large-Scale Association 
Analysis Identifies New Risk Loci for Coronary Artery Disease', Nat Genet, 45 (2013), 
25-33. 
47 C. S. Constantinescu, N. Farooqi, K. O'Brien, and B. Gran, 'Experimental Autoimmune 
Encephalomyelitis (Eae) as a Model for Multiple Sclerosis (Ms)', Br J Pharmacol, 164 
(2011), 1079-106. 
48 A. D. Cook, M. J. Rowley, A. Stockman, K. D. Muirden, and I. R. Mackay, 'Specificity 
of Antibodies to Type Ii Collagen in Early Rheumatoid Arthritis', J Rheumatol, 21 
(1994), 1186-91. 
49 J. Correale, M. C. Ysrraelit, and M. I. Gaitan, 'Vitamin D-Mediated Immune Regulation 
in Multiple Sclerosis', J Neurol Sci, 311 (2011), 23-31. 
50 J. S. Courtenay, M. J. Dallman, A. D. Dayan, A. Martin, and B. Mosedale, 
'Immunisation against Heterologous Type Ii Collagen Induces Arthritis in Mice', 
Nature, 283 (1980), 666-8. 
51 J. E. Craft, 'Follicular Helper T Cells in Immunity and Systemic Autoimmunity', Nat 
Rev Rheumatol, 8 (2012), 337-47. 
52 J. A. Da Silva, and G. M. Hall, 'The Effects of Gender and Sex Hormones on Outcome 
in Rheumatoid Arthritis', Baillieres Clin Rheumatol, 6 (1992), 196-219. 
 50 
53 M. H. Davidson, 'Update on Cetp Inhibition', J Clin Lipidol, 4 (2010), 394-8. 
54 T. Decker, M. Pasca di Magliano, S. McManus, Q. Sun, C. Bonifer, H. Tagoh, and M. 
Busslinger, 'Stepwise Activation of Enhancer and Promoter Regions of the B Cell 
Commitment Gene Pax5 in Early Lymphopoiesis', Immunity, 30 (2009), 508-20. 
55 A. L. DeFranco, 'The Germinal Center Antibody Response in Health and Disease', 
F1000Res, 5 (2016). 
56 A. Delogu, A. Schebesta, Q. Sun, K. Aschenbrenner, T. Perlot, and M. Busslinger, 
'Gene Repression by Pax5 in B Cells Is Essential for Blood Cell Homeostasis and Is 
Reversed in Plasma Cells', Immunity, 24 (2006), 269-81. 
57 Y. Deng, and B. P. Tsao, 'Advances in Lupus Genetics and Epigenetics', Curr Opin 
Rheumatol, 26 (2014), 482-92. 
58 H. S. Dengler, G. V. Baracho, S. A. Omori, S. Bruckner, K. C. Arden, D. H. Castrillon, 
R. A. DePinho, and R. C. Rickert, 'Distinct Functions for the Transcription Factor 
Foxo1 at Various Stages of B Cell Differentiation', Nat Immunol, 9 (2008), 1388-98. 
59 H. Douna, and J. Kuiper, 'Novel B-Cell Subsets in Atherosclerosis', Curr Opin Lipidol, 
27 (2016), 493-8. 
60 G. C. Ebers, D. E. Bulman, A. D. Sadovnick, D. W. Paty, S. Warren, W. Hader, T. J. 
Murray, T. P. Seland, P. Duquette, T. Grey, and et al., 'A Population-Based Study of 
Multiple Sclerosis in Twins', N Engl J Med, 315 (1986), 1638-42. 
61 J. C. Edwards, and G. Cambridge, 'Sustained Improvement in Rheumatoid Arthritis 
Following a Protocol Designed to Deplete B Lymphocytes', Rheumatology (Oxford), 
40 (2001), 205-11. 
62 T. Egawa, B. Albrecht, B. Favier, M. J. Sunshine, K. Mirchandani, W. O'Brien, M. 
Thome, and D. R. Littman, 'Requirement for Carma1 in Antigen Receptor-Induced Nf-
Kappa B Activation and Lymphocyte Proliferation', Curr Biol, 13 (2003), 1252-8. 
63 P. Emery, R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, 
A. Kavanaugh, A. J. Racewicz, R. F. van Vollenhoven, N. F. Li, S. Agarwal, E. W. 
Hessey, T. M. Shaw, and Dancer Study Group, 'The Efficacy and Safety of Rituximab 
in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment: Results 
of a Phase Iib Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial', 
Arthritis Rheum, 54 (2006), 1390-400. 
64 J. G. Evans, K. A. Chavez-Rueda, A. Eddaoudi, A. Meyer-Bahlburg, D. J. Rawlings, 
M. R. Ehrenstein, and C. Mauri, 'Novel Suppressive Function of Transitional 2 B Cells 
in Experimental Arthritis', J Immunol, 178 (2007), 7868-78. 
65 S. Eyre, J. Bowes, D. Diogo, A. Lee, A. Barton, P. Martin, A. Zhernakova, E. Stahl, S. 
Viatte, K. McAllister, C. I. Amos, L. Padyukov, R. E. Toes, T. W. Huizinga, C. 
Wijmenga, G. Trynka, L. Franke, H. J. Westra, L. Alfredsson, X. Hu, C. Sandor, P. I. 
  51 
de Bakker, S. Davila, C. C. Khor, K. K. Heng, R. Andrews, S. Edkins, S. E. Hunt, C. 
Langford, D. Symmons, Genetics Biologics in Rheumatoid Arthritis, Syndicate 
Genomics Study, Consortium Wellcome Trust Case Control, P. Concannon, S. 
Onengut-Gumuscu, S. S. Rich, P. Deloukas, M. A. Gonzalez-Gay, L. Rodriguez-
Rodriguez, L. Arlsetig, J. Martin, S. Rantapaa-Dahlqvist, R. M. Plenge, S. 
Raychaudhuri, L. Klareskog, P. K. Gregersen, and J. Worthington, 'High-Density 
Genetic Mapping Identifies New Susceptibility Loci for Rheumatoid Arthritis', Nat 
Genet, 44 (2012), 1336-40. 
66 D. Fairweather, S. Frisancho-Kiss, and N. R. Rose, 'Sex Differences in Autoimmune 
Disease from a Pathological Perspective', Am J Pathol, 173 (2008), 600-9. 
67 I. Ferreiros-Vidal, T. Carroll, B. Taylor, A. Terry, Z. Liang, L. Bruno, G. 
Dharmalingam, S. Khadayate, B. S. Cobb, S. T. Smale, M. Spivakov, P. Srivastava, E. 
Petretto, A. G. Fisher, and M. Merkenschlager, 'Genome-Wide Identification of Ikaros 
Targets Elucidates Its Contribution to Mouse B-Cell Lineage Specification and Pre-B-
Cell Differentiation', Blood, 121 (2013), 1769-82. 
68 S. Fillatreau, C. H. Sweenie, M. J. McGeachy, D. Gray, and S. M. Anderton, 'B Cells 
Regulate Autoimmunity by Provision of Il-10', Nat Immunol, 3 (2002), 944-50. 
69 R. Fiskesund, J. Steen, K. Amara, F. Murray, A. Szwajda, A. Liu, I. Douagi, V. 
Malmstrom, and J. Frostegard, 'Naturally Occurring Human Phosphorylcholine 
Antibodies Are Predominantly Products of Affinity-Matured B Cells in the Adult', J 
Immunol, 192 (2014), 4551-9. 
70 I. Forster, and K. Rajewsky, 'The Bulk of the Peripheral B-Cell Pool in Mice Is Stable 
and Not Rapidly Renewed from the Bone Marrow', Proc Natl Acad Sci U S A, 87 
(1990), 4781-4. 
71 A. G. Frostegard, J. Su, X. Hua, M. Vikstrom, U. de Faire, and J. Frostegard, 
'Antibodies against Native and Oxidized Cardiolipin and Phosphatidylserine and 
Phosphorylcholine in Atherosclerosis Development', PLoS One, 9 (2014), e111764. 
72 M. H. Garcia-Hernandez, R. Gonzalez-Amaro, and D. P. Portales-Perez, 'Specific 
Therapy to Regulate Inflammation in Rheumatoid Arthritis: Molecular Aspects', 
Immunotherapy, 6 (2014), 623-36. 
73 M. C. Genovese, J. L. Kaine, M. B. Lowenstein, J. Del Giudice, A. Baldassare, J. 
Schechtman, E. Fudman, M. Kohen, S. Gujrathi, R. G. Trapp, N. J. Sweiss, G. 
Spaniolo, W. Dummer, and Action Study Group, 'Ocrelizumab, a Humanized Anti-
Cd20 Monoclonal Antibody, in the Treatment of Patients with Rheumatoid Arthritis: 
A Phase I/Ii Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study', Arthritis 
Rheum, 58 (2008), 2652-61. 
74 P. Georgiades, S. Ogilvy, H. Duval, D. R. Licence, D. S. Charnock-Jones, S. K. Smith, 
and C. G. Print, 'Vavcre Transgenic Mice: A Tool for Mutagenesis in Hematopoietic 
and Endothelial Lineages', Genesis, 34 (2002), 251-6. 
 52 
75 K. Georgopoulos, 'Haematopoietic Cell-Fate Decisions, Chromatin Regulation and 
Ikaros', Nat Rev Immunol, 2 (2002), 162-74. 
76 G. S. Getz, and C. A. Reardon, 'Animal Models of Atherosclerosis', Arterioscler 
Thromb Vasc Biol, 32 (2012), 1104-15. 
77 C. K. Glass, and J. L. Witztum, 'Atherosclerosis. The Road Ahead', Cell, 104 (2001), 
503-16. 
78 E. K. Grasset, A. Duhlin, H. E. Agardh, O. Ovchinnikova, T. Hagglof, M. N. Forsell, 
G. Paulsson-Berne, G. K. Hansson, D. F. Ketelhuth, and M. C. Karlsson, 'Sterile 
Inflammation in the Spleen During Atherosclerosis Provides Oxidation-Specific 
Epitopes That Induce a Protective B-Cell Response', Proc Natl Acad Sci U S A, 112 
(2015), E2030-8. 
79 M. Gray, K. Miles, D. Salter, D. Gray, and J. Savill, 'Apoptotic Cells Protect Mice from 
Autoimmune Inflammation by the Induction of Regulatory B Cells', Proc Natl Acad 
Sci U S A, 104 (2007), 14080-5. 
80 M. Gunnarsson, C. Malmestrom, M. Axelsson, P. Sundstrom, C. Dahle, M. Vrethem, 
T. Olsson, F. Piehl, N. Norgren, L. Rosengren, A. Svenningsson, and J. Lycke, 'Axonal 
Damage in Relapsing Multiple Sclerosis Is Markedly Reduced by Natalizumab', Ann 
Neurol, 69 (2011), 83-9. 
81 K. M. Haas, R. Watanabe, T. Matsushita, H. Nakashima, N. Ishiura, H. Okochi, M. 
Fujimoto, and T. F. Tedder, 'Protective and Pathogenic Roles for B Cells During 
Systemic Autoimmunity in Nzb/W F1 Mice', J Immunol, 184 (2010), 4789-800. 
82 J. Halfvarson, L. Bodin, C. Tysk, E. Lindberg, and G. Jarnerot, 'Inflammatory Bowel 
Disease in a Swedish Twin Cohort: A Long-Term Follow-up of Concordance and 
Clinical Characteristics', Gastroenterology, 124 (2003), 1767-73. 
83 J. W. Han, H. F. Zheng, Y. Cui, L. D. Sun, D. Q. Ye, Z. Hu, J. H. Xu, Z. M. Cai, W. 
Huang, G. P. Zhao, H. F. Xie, H. Fang, Q. J. Lu, J. H. Xu, X. P. Li, Y. F. Pan, D. Q. 
Deng, F. Q. Zeng, Z. Z. Ye, X. Y. Zhang, Q. W. Wang, F. Hao, L. Ma, X. B. Zuo, F. 
S. Zhou, W. H. Du, Y. L. Cheng, J. Q. Yang, S. K. Shen, J. Li, Y. J. Sheng, X. X. Zuo, 
W. F. Zhu, F. Gao, P. L. Zhang, Q. Guo, B. Li, M. Gao, F. L. Xiao, C. Quan, C. Zhang, 
Z. Zhang, K. J. Zhu, Y. Li, D. Y. Hu, W. S. Lu, J. L. Huang, S. X. Liu, H. Li, Y. Q. 
Ren, Z. X. Wang, C. J. Yang, P. G. Wang, W. M. Zhou, Y. M. Lv, A. P. Zhang, S. Q. 
Zhang, D. Lin, Y. Li, H. Q. Low, M. Shen, Z. F. Zhai, Y. Wang, F. Y. Zhang, S. Yang, 
J. J. Liu, and X. J. Zhang, 'Genome-Wide Association Study in a Chinese Han 
Population Identifies Nine New Susceptibility Loci for Systemic Lupus 
Erythematosus', Nat Genet, 41 (2009), 1234-7. 
84 S. Han, S. Cao, R. Bheekha-Escura, and B. Zheng, 'Germinal Center Reaction in the 
Joints of Mice with Collagen-Induced Arthritis: An Animal Model of Lymphocyte 
Activation and Differentiation in Arthritis Joints', Arthritis Rheum, 44 (2001), 1438-43. 
  53 
85 X. Han, and W. A. Boisvert, 'Interleukin-10 Protects against Atherosclerosis by 
Modulating Multiple Atherogenic Macrophage Function', Thromb Haemost, 113 
(2015), 505-12. 
86 G. K. Hansson, and P. Libby, 'The Immune Response in Atherosclerosis: A Double-
Edged Sword', Nat Rev Immunol, 6 (2006), 508-19. 
87 R. R. Hardy, and K. Hayakawa, 'B Cell Development Pathways', Annu Rev Immunol, 
19 (2001), 595-621. 
88 ———, 'Perspectives on Fetal Derived Cd5+ B1 B Cells', Eur J Immunol, 45 (2015), 
2978-84. 
89 S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. 
Panzara, N. Sarkar, S. Agarwal, A. Langer-Gould, C. H. Smith, and Hermes Trial 
Group, 'B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis', 
N Engl J Med, 358 (2008), 676-88. 
90 K. Hayakawa, A. M. Formica, M. J. Colombo, D. Ichikawa, S. A. Shinton, J. Brill-
Dashoff, and R. R. Hardy, 'B Cells Generated by B-1 Development Can Progress to 
Chronic Lymphocytic Leukemia', Ann N Y Acad Sci, 1362 (2015), 250-5. 
91 K. Hayakawa, and R. R. Hardy, 'Normal, Autoimmune, and Malignant Cd5+ B Cells: 
The Ly-1 B Lineage?', Annu Rev Immunol, 6 (1988), 197-218. 
92 K. Hayakawa, R. R. Hardy, M. Honda, L. A. Herzenberg, A. D. Steinberg, and L. A. 
Herzenberg, 'Ly-1 B Cells: Functionally Distinct Lymphocytes That Secrete Igm 
Autoantibodies', Proc Natl Acad Sci U S A, 81 (1984), 2494-8. 
93 K. Hayakawa, R. R. Hardy, D. R. Parks, and L. A. Herzenberg, 'The "Ly-1 B" Cell 
Subpopulation in Normal Immunodefective, and Autoimmune Mice', J Exp Med, 157 
(1983), 202-18. 
94 K. Hayakawa, R. R. Hardy, A. M. Stall, L. A. Herzenberg, and L. A. Herzenberg, 
'Immunoglobulin-Bearing B Cells Reconstitute and Maintain the Murine Ly-1 B Cell 
Lineage', Eur J Immunol, 16 (1986), 1313-6. 
95 S. M. Hayter, and M. C. Cook, 'Updated Assessment of the Prevalence, Spectrum and 
Case Definition of Autoimmune Disease', Autoimmun Rev, 11 (2012), 754-65. 
96 C. M. Hedrich, T. Rauen, S. A. Apostolidis, A. P. Grammatikos, N. Rodriguez 
Rodriguez, C. Ioannidis, V. C. Kyttaris, J. C. Crispin, and G. C. Tsokos, 'Stat3 Promotes 
Il-10 Expression in Lupus T Cells through Trans-Activation and Chromatin 
Remodeling', Proc Natl Acad Sci U S A, 111 (2014), 13457-62. 
97 C. G. Helmick, D. T. Felson, R. C. Lawrence, S. Gabriel, R. Hirsch, C. K. Kwoh, M. 
H. Liang, H. M. Kremers, M. D. Mayes, P. A. Merkel, S. R. Pillemer, J. D. Reveille, J. 
H. Stone, and Workgroup National Arthritis Data, 'Estimates of the Prevalence of 
 54 
Arthritis and Other Rheumatic Conditions in the United States. Part I', Arthritis Rheum, 
58 (2008), 15-25. 
98 T. S. Heng, M. W. Painter, and Consortium Immunological Genome Project, 'The 
Immunological Genome Project: Networks of Gene Expression in Immune Cells', Nat 
Immunol, 9 (2008), 1091-4. 
99 R. F. Herrscher, M. H. Kaplan, D. L. Lelsz, C. Das, R. Scheuermann, and P. W. Tucker, 
'The Immunoglobulin Heavy-Chain Matrix-Associating Regions Are Bound by Bright: 
A B Cell-Specific Trans-Activator That Describes a New DNA-Binding Protein 
Family', Genes Dev, 9 (1995), 3067-82. 
100 L. A. Hindorff, P. Sethupathy, H. A. Junkins, E. M. Ramos, J. P. Mehta, F. S. Collins, 
and T. A. Manolio, 'Potential Etiologic and Functional Implications of Genome-Wide 
Association Loci for Human Diseases and Traits', Proc Natl Acad Sci U S A, 106 
(2009), 9362-7. 
101 E. Hobeika, S. Thiemann, B. Storch, H. Jumaa, P. J. Nielsen, R. Pelanda, and M. Reth, 
'Testing Gene Function Early in the B Cell Lineage in Mb1-Cre Mice', Proc Natl Acad 
Sci U S A, 103 (2006), 13789-94. 
102 H. H. Hofstetter, C. L. Shive, and T. G. Forsthuber, 'Pertussis Toxin Modulates the 
Immune Response to Neuroantigens Injected in Incomplete Freund's Adjuvant: 
Induction of Th1 Cells and Experimental Autoimmune Encephalomyelitis in the 
Presence of High Frequencies of Th2 Cells', J Immunol, 169 (2002), 117-25. 
103 R. Holmdahl, L. Jansson, M. Andersson, and E. Larsson, 'Immunogenetics of Type Ii 
Collagen Autoimmunity and Susceptibility to Collagen Arthritis', Immunology, 65 
(1988), 305-10. 
104 R. Holmdahl, L. Jansson, E. Larsson, K. Rubin, and L. Klareskog, 'Homologous Type 
Ii Collagen Induces Chronic and Progressive Arthritis in Mice', Arthritis Rheum, 29 
(1986), 106-13. 
105 B. Hou, P. Saudan, G. Ott, M. L. Wheeler, M. Ji, L. Kuzmich, L. M. Lee, R. L. 
Coffman, M. F. Bachmann, and A. L. DeFranco, 'Selective Utilization of Toll-Like 
Receptor and Myd88 Signaling in B Cells for Enhancement of the Antiviral Germinal 
Center Response', Immunity, 34 (2011), 375-84. 
106 T. Huan, B. Zhang, Z. Wang, R. Joehanes, J. Zhu, A. D. Johnson, S. Ying, P. J. Munson, 
N. Raghavachari, R. Wang, P. Liu, P. Courchesne, S. J. Hwang, T. L. Assimes, R. 
McPherson, N. J. Samani, H. Schunkert, ARteryDIsease Genome wide Replication 
Coronary, International Consortium for Blood Pressure Gwas Meta-analysis 
Consortium, Q. Meng, C. Suver, C. J. O'Donnell, J. Derry, X. Yang, and D. Levy, 'A 
Systems Biology Framework Identifies Molecular Underpinnings of Coronary Heart 
Disease', Arterioscler Thromb Vasc Biol, 33 (2013), 1427-34. 
  55 
107 M. Ichii, T. Shimazu, R. S. Welner, K. P. Garrett, Q. Zhang, B. L. Esplin, and P. W. 
Kincade, 'Functional Diversity of Stem and Progenitor Cells with B-Lymphopoietic 
Potential', Immunol Rev, 237 (2010), 10-21. 
108 J. B. Imboden, 'The Immunopathogenesis of Rheumatoid Arthritis', Annu Rev Pathol, 
4 (2009), 417-34. 
109 Camms Trial Investigators, A. J. Coles, D. A. Compston, K. W. Selmaj, S. L. Lake, S. 
Moran, D. H. Margolin, K. Norris, and P. K. Tandon, 'Alemtuzumab Vs. Interferon 
Beta-1a in Early Multiple Sclerosis', N Engl J Med, 359 (2008), 1786-801. 
110 A. Ito, B. F. Bebo, Jr., A. Matejuk, A. Zamora, M. Silverman, A. Fyfe-Johnson, and H. 
Offner, 'Estrogen Treatment Down-Regulates Tnf-Alpha Production and Reduces the 
Severity of Experimental Autoimmune Encephalomyelitis in Cytokine Knockout 
Mice', J Immunol, 167 (2001), 542-52. 
111 S. W. Jackson, N. S. Kolhatkar, and D. J. Rawlings, 'B Cells Take the Front Seat: 
Dysregulated B Cell Signals Orchestrate Loss of Tolerance and Autoantibody 
Production', Curr Opin Immunol, 33 (2015), 70-7. 
112 D. L. Jacobson, S. J. Gange, N. R. Rose, and N. M. Graham, 'Epidemiology and 
Estimated Population Burden of Selected Autoimmune Diseases in the United States', 
Clin Immunol Immunopathol, 84 (1997), 223-43. 
113 C. A. Janeway, Jr., and R. Medzhitov, 'Innate Immune Recognition', Annu Rev 
Immunol, 20 (2002), 197-216. 
114 J. L. Jones, J. M. Anderson, C. L. Phuah, E. J. Fox, K. Selmaj, D. Margolin, S. L. Lake, 
J. Palmer, S. J. Thompson, A. Wilkins, D. J. Webber, D. A. Compston, and A. J. Coles, 
'Improvement in Disability after Alemtuzumab Treatment of Multiple Sclerosis Is 
Associated with Neuroprotective Autoimmunity', Brain, 133 (2010), 2232-47. 
115 E. A. Kabat, D. A. Freedman, and et al., 'A Study of the Crystalline Albumin, Gamma 
Globulin and Total Protein in the Cerebrospinal Fluid of 100 Cases of Multiple 
Sclerosis and in Other Diseases', Am J Med Sci, 219 (1950), 55-64. 
116 J. C. Kagan, 'Signaling Organelles of the Innate Immune System', Cell, 151 (2012), 
1168-78. 
117 K. Kannan, R. A. Ortmann, and D. Kimpel, 'Animal Models of Rheumatoid Arthritis 
and Their Relevance to Human Disease', Pathophysiology, 12 (2005), 167-81. 
118 T. Kawai, and S. Akira, 'The Role of Pattern-Recognition Receptors in Innate 
Immunity: Update on Toll-Like Receptors', Nat Immunol, 11 (2010), 373-84. 
119 H. Kawamoto, and Y. Katsura, 'A New Paradigm for Hematopoietic Cell Lineages: 
Revision of the Classical Concept of the Myeloid-Lymphoid Dichotomy', Trends 
Immunol, 30 (2009), 193-200. 
 56 
120 R. D. Kortschak, P. W. Tucker, and R. Saint, 'Arid Proteins Come in from the Desert', 
Trends Biochem Sci, 25 (2000), 294-9. 
121 C. Kosan, I. Saba, M. Godmann, S. Herold, B. Herkert, M. Eilers, and T. Moroy, 
'Transcription Factor Miz-1 Is Required to Regulate Interleukin-7 Receptor Signaling 
at Early Commitment Stages of B Cell Differentiation', Immunity, 33 (2010), 917-28. 
122 H. S. Kuehn, W. Ouyang, B. Lo, E. K. Deenick, J. E. Niemela, D. T. Avery, J. N. 
Schickel, D. Q. Tran, J. Stoddard, Y. Zhang, D. M. Frucht, B. Dumitriu, P. Scheinberg, 
L. R. Folio, C. A. Frein, S. Price, C. Koh, T. Heller, C. M. Seroogy, A. Huttenlocher, 
V. K. Rao, H. C. Su, D. Kleiner, L. D. Notarangelo, Y. Rampertaap, K. N. Olivier, J. 
McElwee, J. Hughes, S. Pittaluga, J. B. Oliveira, E. Meffre, T. A. Fleisher, S. M. 
Holland, M. J. Lenardo, S. G. Tangye, and G. Uzel, 'Immune Dysregulation in Human 
Subjects with Heterozygous Germline Mutations in Ctla4', Science, 345 (2014), 1623-
27. 
123 J. L. Kurkewich, N. Klopfenstein, W. M. Hallas, C. Wood, R. A. Sattler, C. Das, H. 
Tucker, R. Dahl, and K. D. Cowden Dahl, 'Arid3b Is Critical for B Lymphocyte 
Development', PLoS One, 11 (2016), e0161468. 
124 T. Kyaw, P. Tipping, A. Bobik, and B. H. Toh, 'Protective Role of Natural Igm-
Producing B1a Cells in Atherosclerosis', Trends Cardiovasc Med, 22 (2012), 48-53. 
125 M. L. Lang, 'How Do Natural Killer T Cells Help B Cells?', Expert Rev Vaccines, 8 
(2009), 1109-21. 
126 L. L. Lanier, and J. C. Sun, 'Do the Terms Innate and Adaptive Immunity Create 
Conceptual Barriers?', Nat Rev Immunol, 9 (2009), 302-3. 
127 Y. S. Li, Y. Zhou, L. Tang, S. A. Shinton, K. Hayakawa, and R. R. Hardy, 'A 
Developmental Switch between Fetal and Adult B Lymphopoiesis', Ann N Y Acad Sci, 
1362 (2015), 8-15. 
128 H. Lin, and R. Grosschedl, 'Failure of B-Cell Differentiation in Mice Lacking the 
Transcription Factor Ebf', Nature, 376 (1995), 263-7. 
129 Y. C. Lin, S. Jhunjhunwala, C. Benner, S. Heinz, E. Welinder, R. Mansson, M. 
Sigvardsson, J. Hagman, C. A. Espinoza, J. Dutkowski, T. Ideker, C. K. Glass, and C. 
Murre, 'A Global Network of Transcription Factors, Involving E2a, Ebf1 and Foxo1, 
That Orchestrates B Cell Fate', Nat Immunol, 11 (2010), 635-43. 
130 Y. Lin, Z. Chen, and S. Kato, 'Receptor-Selective Il-4 Mutein Modulates Inflammatory 
Vascular Cell Phenotypes and Attenuates Atherogenesis in Apolipoprotein E-
Knockout Mice', Exp Mol Pathol, 99 (2015), 116-27. 
131 M. M. Lipton, and J. Freund, 'The Transfer of Experimental Allergic Encephalomyelitis 
in the Rat by Means of Parabiosis', J Immunol, 71 (1953), 380-4. 
  57 
132 F. Loder, B. Mutschler, R. J. Ray, C. J. Paige, P. Sideras, R. Torres, M. C. Lamers, and 
R. Carsetti, 'B Cell Development in the Spleen Takes Place in Discrete Steps and Is 
Determined by the Quality of B Cell Receptor-Derived Signals', J Exp Med, 190 (1999), 
75-89. 
133 J. E. Lortan, C. A. Roobottom, S. Oldfield, and I. C. MacLennan, 'Newly Produced 
Virgin B Cells Migrate to Secondary Lymphoid Organs but Their Capacity to Enter 
Follicles Is Restricted', Eur J Immunol, 17 (1987), 1311-6. 
134 Q. Lu, A. Wu, L. Tesmer, D. Ray, N. Yousif, and B. Richardson, 'Demethylation of 
Cd40lg on the Inactive X in T Cells from Women with Lupus', J Immunol, 179 (2007), 
6352-8. 
135 R. Lu, N. F. Neff, S. R. Quake, and I. L. Weissman, 'Tracking Single Hematopoietic 
Stem Cells in Vivo Using High-Throughput Sequencing in Conjunction with Viral 
Genetic Barcoding', Nat Biotechnol, 29 (2011), 928-33. 
136 A. Macias-Garcia, B. Heizmann, M. Sellars, P. Marchal, H. Dali, J. L. Pasquali, S. 
Muller, P. Kastner, and S. Chan, 'Ikaros Is a Negative Regulator of B1 Cell 
Development and Function', J Biol Chem, 291 (2016), 9073-86. 
137 Z. Mallat, S. Besnard, M. Duriez, V. Deleuze, F. Emmanuel, M. F. Bureau, F. Soubrier, 
B. Esposito, H. Duez, C. Fievet, B. Staels, N. Duverger, D. Scherman, and A. Tedgui, 
'Protective Role of Interleukin-10 in Atherosclerosis', Circ Res, 85 (1999), e17-24. 
138 R. Mansson, S. Zandi, E. Welinder, P. Tsapogas, N. Sakaguchi, D. Bryder, and M. 
Sigvardsson, 'Single-Cell Analysis of the Common Lymphoid Progenitor 
Compartment Reveals Functional and Molecular Heterogeneity', Blood, 115 (2010), 
2601-9. 
139 T. E. Markatseli, C. Papagoras, A. Nikoli, P. V. Voulgari, and A. A. Drosos, 
'Certolizumab for Rheumatoid Arthritis', Clin Exp Rheumatol, 32 (2014), 415-23. 
140 T. Matsushita, M. Horikawa, Y. Iwata, and T. F. Tedder, 'Regulatory B Cells (B10 
Cells) and Regulatory T Cells Have Independent Roles in Controlling Experimental 
Autoimmune Encephalomyelitis Initiation and Late-Phase Immunopathogenesis', J 
Immunol, 185 (2010), 2240-52. 
141 T. Matsushita, K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder, 'Regulatory 
B Cells Inhibit Eae Initiation in Mice While Other B Cells Promote Disease 
Progression', J Clin Invest, 118 (2008), 3420-30. 
142 C. Mauri, D. Gray, N. Mushtaq, and M. Londei, 'Prevention of Arthritis by Interleukin 
10-Producing B Cells', J Exp Med, 197 (2003), 489-501. 
143 I. B. McInnes, and G. Schett, 'The Pathogenesis of Rheumatoid Arthritis', N Engl J 
Med, 365 (2011), 2205-19. 
 58 
144 J. Medvedovic, A. Ebert, H. Tagoh, and M. Busslinger, 'Pax5: A Master Regulator of 
B Cell Development and Leukemogenesis', Adv Immunol, 111 (2011), 179-206. 
145 R. Medzhitov, 'Origin and Physiological Roles of Inflammation', Nature, 454 (2008), 
428-35. 
146 F. Melchers, 'The Pre-B-Cell Receptor: Selector of Fitting Immunoglobulin Heavy 
Chains for the B-Cell Repertoire', Nat Rev Immunol, 5 (2005), 578-84. 
147 N. E. Miller, 'Associations of High-Density Lipoprotein Subclasses and 
Apolipoproteins with Ischemic Heart Disease and Coronary Atherosclerosis', Am Heart 
J, 113 (1987), 589-97. 
148 P. Minoprio, O. Burlen, P. Pereira, B. Guilbert, L. Andrade, M. Hontebeyrie-
Joskowicz, and A. Coutinho, 'Most B Cells in Acute Trypanosoma Cruzi Infection Lack 
Parasite Specificity', Scand J Immunol, 28 (1988), 553-61. 
149 A. Mizoguchi, and A. K. Bhan, 'A Case for Regulatory B Cells', J Immunol, 176 (2006), 
705-10. 
150 A. Mizoguchi, E. Mizoguchi, R. N. Smith, F. I. Preffer, and A. K. Bhan, 'Suppressive 
Role of B Cells in Chronic Colitis of T Cell Receptor Alpha Mutant Mice', J Exp Med, 
186 (1997), 1749-56. 
151 E. Mizoguchi, A. Mizoguchi, F. I. Preffer, and A. K. Bhan, 'Regulatory Role of Mature 
B Cells in a Murine Model of Inflammatory Bowel Disease', Int Immunol, 12 (2000), 
597-605. 
152 E. Montecino-Rodriguez, and K. Dorshkind, 'B-1 B Cell Development in the Fetus and 
Adult', Immunity, 36 (2012), 13-21. 
153 E. Montecino-Rodriguez, K. Li, M. Fice, and K. Dorshkind, 'Murine B-1 B Cell 
Progenitors Initiate B-Acute Lymphoblastic Leukemia with Features of High-Risk 
Disease', J Immunol, 192 (2014), 5171-8. 
154 T. Moroy, and C. Khandanpour, 'Growth Factor Independence 1 (Gfi1) as a Regulator 
of Lymphocyte Development and Activation', Semin Immunol, 23 (2011), 368-78. 
155 S. Muller, and M. Radic, 'Citrullinated Autoantigens: From Diagnostic Markers to 
Pathogenetic Mechanisms', Clin Rev Allergy Immunol, 49 (2015), 232-9. 
156 Kenneth Murphy, Paul Travers, Mark Walport, and Charles Janeway, Janeway's 
Immunobiology (New York: Garland Science, 2011). 
157 Y. Nakashima, A. S. Plump, E. W. Raines, J. L. Breslow, and R. Ross, 'Apoe-Deficient 
Mice Develop Lesions of All Phases of Atherosclerosis Throughout the Arterial Tree', 
Arterioscler Thromb, 14 (1994), 133-40. 
  59 
158 C. Nathan, and A. Ding, 'Nonresolving Inflammation', Cell, 140 (2010), 871-82. 
159 R. Nechanitzky, D. Akbas, S. Scherer, I. Gyory, T. Hoyler, S. Ramamoorthy, A. 
Diefenbach, and R. Grosschedl, 'Transcription Factor Ebf1 Is Essential for the 
Maintenance of B Cell Identity and Prevention of Alternative Fates in Committed 
Cells', Nat Immunol, 14 (2013), 867-75. 
160 J. Neefjes, M. L. Jongsma, P. Paul, and O. Bakke, 'Towards a Systems Understanding 
of Mhc Class I and Mhc Class Ii Antigen Presentation', Nat Rev Immunol, 11 (2011), 
823-36. 
161 T. Nemeth, K. Futosi, C. Sitaru, J. Ruland, and A. Mocsai, 'Neutrophil-Specific 
Deletion of the Card9 Gene Expression Regulator Suppresses Autoantibody-Induced 
Inflammation in Vivo', Nat Commun, 7 (2016), 11004. 
162 T. B. Niewold, 'Advances in Lupus Genetics', Curr Opin Rheumatol, 27 (2015), 440-
7. 
163 M. Nikpay, A. Goel, H. H. Won, L. M. Hall, C. Willenborg, S. Kanoni, D. Saleheen, 
T. Kyriakou, C. P. Nelson, J. C. Hopewell, T. R. Webb, L. Zeng, A. Dehghan, M. Alver, 
S. M. Armasu, K. Auro, A. Bjonnes, D. I. Chasman, S. Chen, I. Ford, N. Franceschini, 
C. Gieger, C. Grace, S. Gustafsson, J. Huang, S. J. Hwang, Y. K. Kim, M. E. Kleber, 
K. W. Lau, X. Lu, Y. Lu, L. P. Lyytikainen, E. Mihailov, A. C. Morrison, N. 
Pervjakova, L. Qu, L. M. Rose, E. Salfati, R. Saxena, M. Scholz, A. V. Smith, E. 
Tikkanen, A. Uitterlinden, X. Yang, W. Zhang, W. Zhao, M. de Andrade, P. S. de Vries, 
N. R. van Zuydam, S. S. Anand, L. Bertram, F. Beutner, G. Dedoussis, P. Frossard, D. 
Gauguier, A. H. Goodall, O. Gottesman, M. Haber, B. G. Han, J. Huang, S. Jalilzadeh, 
T. Kessler, I. R. Konig, L. Lannfelt, W. Lieb, L. Lind, C. M. Lindgren, M. L. Lokki, P. 
K. Magnusson, N. H. Mallick, N. Mehra, T. Meitinger, F. U. Memon, A. P. Morris, M. 
S. Nieminen, N. L. Pedersen, A. Peters, L. S. Rallidis, A. Rasheed, M. Samuel, S. H. 
Shah, J. Sinisalo, K. E. Stirrups, S. Trompet, L. Wang, K. S. Zaman, D. Ardissino, E. 
Boerwinkle, I. B. Borecki, E. P. Bottinger, J. E. Buring, J. C. Chambers, R. Collins, L. 
A. Cupples, J. Danesh, I. Demuth, R. Elosua, S. E. Epstein, T. Esko, M. F. Feitosa, O. 
H. Franco, M. G. Franzosi, C. B. Granger, D. Gu, V. Gudnason, A. S. Hall, A. Hamsten, 
T. B. Harris, S. L. Hazen, C. Hengstenberg, A. Hofman, E. Ingelsson, C. Iribarren, J. 
W. Jukema, P. J. Karhunen, B. J. Kim, J. S. Kooner, I. J. Kullo, T. Lehtimaki, R. J. F. 
Loos, O. Melander, A. Metspalu, W. Marz, C. N. Palmer, M. Perola, T. Quertermous, 
D. J. Rader, P. M. Ridker, S. Ripatti, R. Roberts, V. Salomaa, D. K. Sanghera, S. M. 
Schwartz, U. Seedorf, A. F. Stewart, D. J. Stott, J. Thiery, P. A. Zalloua, C. J. 
O'Donnell, M. P. Reilly, T. L. Assimes, J. R. Thompson, J. Erdmann, R. Clarke, H. 
Watkins, S. Kathiresan, R. McPherson, P. Deloukas, H. Schunkert, N. J. Samani, and 
M. Farrall, 'A Comprehensive 1,000 Genomes-Based Genome-Wide Association 
Meta-Analysis of Coronary Artery Disease', Nat Genet, 47 (2015), 1121-30. 
164 J. C. Nixon, S. Ferrell, C. Miner, A. L. Oldham, U. Hochgeschwender, and C. F. Webb, 
'Transgenic Mice Expressing Dominant-Negative Bright Exhibit Defects in B1 B 
Cells', J Immunol, 181 (2008), 6913-22. 
 60 
165 J. C. Nixon, J. B. Rajaiya, N. Ayers, S. Evetts, and C. F. Webb, 'The Transcription 
Factor, Bright, Is Not Expressed in All Human B Lymphocyte Subpopulations', Cell 
Immunol, 228 (2004), 42-53. 
166 S. L. Nutt, D. Eberhard, M. Horcher, A. G. Rolink, and M. Busslinger, 'Pax5 
Determines the Identity of B Cells from the Beginning to the End of B-Lymphopoiesis', 
Int Rev Immunol, 20 (2001), 65-82. 
167 S. L. Nutt, B. Heavey, A. G. Rolink, and M. Busslinger, 'Commitment to the B-
Lymphoid Lineage Depends on the Transcription Factor Pax5', Nature, 401 (1999), 
556-62. 
168 S. L. Nutt, and B. L. Kee, 'The Transcriptional Regulation of B Cell Lineage 
Commitment', Immunity, 26 (2007), 715-25. 
169 S. L. Nutt, P. Urbanek, A. Rolink, and M. Busslinger, 'Essential Functions of Pax5 
(Bsap) in Pro-B Cell Development: Difference between Fetal and Adult B 
Lymphopoiesis and Reduced V-to-Dj Recombination at the Igh Locus', Genes Dev, 11 
(1997), 476-91. 
170 A. Nylander, and D. A. Hafler, 'Multiple Sclerosis', J Clin Invest, 122 (2012), 1180-8. 
171 A. O'Garra, R. Chang, N. Go, R. Hastings, G. Haughton, and M. Howard, 'Ly-1 B (B-
1) Cells Are the Main Source of B Cell-Derived Interleukin 10', Eur J Immunol, 22 
(1992), 711-7. 
172 K. Oelke, Q. Lu, D. Richardson, A. Wu, C. Deng, S. Hanash, and B. Richardson, 
'Overexpression of Cd70 and Overstimulation of Igg Synthesis by Lupus T Cells and 
T Cells Treated with DNA Methylation Inhibitors', Arthritis Rheum, 50 (2004), 1850-
60. 
173 P. K. Olitsky, and R. H. Yager, 'Experimental Disseminated Encephalomyelitis in 
White Mice', J Exp Med, 90 (1949), 213-24. 
174 P. Olmos, R. A'Hern, D. A. Heaton, B. A. Millward, D. Risley, D. A. Pyke, and R. D. 
Leslie, 'The Significance of the Concordance Rate for Type 1 (Insulin-Dependent) 
Diabetes in Identical Twins', Diabetologia, 31 (1988), 747-50. 
175 P. Olofsson, J. Holmberg, J. Tordsson, S. Lu, B. Akerstrom, and R. Holmdahl, 
'Positional Identification of Ncf1 as a Gene That Regulates Arthritis Severity in Rats', 
Nat Genet, 33 (2003), 25-32. 
176 M. Osiri, B. Shea, V. Robinson, M. Suarez-Almazor, V. Strand, P. Tugwell, and G. 
Wells, 'Leflunomide for the Treatment of Rheumatoid Arthritis: A Systematic Review 
and Metaanalysis', J Rheumatol, 30 (2003), 1182-90. 
177 M. Ostergaard, B. Baslund, W. Rigby, B. Rojkovich, C. Jorgensen, P. T. Dawes, C. 
Wiell, D. J. Wallace, S. C. Tamer, H. Kastberg, J. Petersen, and S. Sierakowski, 
'Ofatumumab, a Human Anti-Cd20 Monoclonal Antibody, for Treatment of 
  61 
Rheumatoid Arthritis with an Inadequate Response to One or More Disease-Modifying 
Antirheumatic Drugs: Results of a Randomized, Double-Blind, Placebo-Controlled, 
Phase I/Ii Study', Arthritis Rheum, 62 (2010), 2227-38. 
178 M. Parkes, A. Cortes, D. A. van Heel, and M. A. Brown, 'Genetic Insights into Common 
Pathways and Complex Relationships among Immune-Mediated Diseases', Nat Rev 
Genet, 14 (2013), 661-73. 
179 P. Y. Paterson, 'Transfer of Allergic Encephalomyelitis in Rats by Means of Lymph 
Node Cells', J Exp Med, 111 (1960), 119-36. 
180 A. Patsialou, D. Wilsker, and E. Moran, 'DNA-Binding Properties of Arid Family 
Proteins', Nucleic Acids Res, 33 (2005), 66-80. 
181 G. K. Pedersen, M. Adori, S. Khoenkhoen, P. Dosenovic, B. Beutler, and G. B. 
Karlsson Hedestam, 'B-1a Transitional Cells Are Phenotypically Distinct and Are 
Lacking in Mice Deficient in Ikappabns', Proc Natl Acad Sci U S A, 111 (2014), E4119-
26. 
182 R. S. Pereira, C. M. Black, V. C. Duance, V. E. Jones, R. K. Jacoby, and K. I. Welsh, 
'Disappearing Collagen Antibodies in Rheumatoid Arthritis', Lancet, 2 (1985), 501-2. 
183 R. L. Perlman, 'Mouse Models of Human Disease: An Evolutionary Perspective', Evol 
Med Public Health, 2016 (2016), 170-6. 
184 H. M. Perry, T. P. Bender, and C. A. McNamara, 'B Cell Subsets in Atherosclerosis', 
Front Immunol, 3 (2012), 373. 
185 R. T. Phan, and R. Dalla-Favera, 'The Bcl6 Proto-Oncogene Suppresses P53 
Expression in Germinal-Centre B Cells', Nature, 432 (2004), 635-9. 
186 E. R. Pierson, I. M. Stromnes, and J. M. Goverman, 'B Cells Promote Induction of 
Experimental Autoimmune Encephalomyelitis by Facilitating Reactivation of T Cells 
in the Central Nervous System', J Immunol, 192 (2014), 929-39. 
187 T. Pohl, R. Gugasyan, R. J. Grumont, A. Strasser, D. Metcalf, D. Tarlinton, W. Sha, D. 
Baltimore, and S. Gerondakis, 'The Combined Absence of Nf-Kappa B1 and C-Rel 
Reveals That Overlapping Roles for These Transcription Factors in the B Cell Lineage 
Are Restricted to the Activation and Function of Mature Cells', Proc Natl Acad Sci U 
S A, 99 (2002), 4514-9. 
188 S. Potteaux, B. Esposito, O. van Oostrom, V. Brun, P. Ardouin, H. Groux, A. Tedgui, 
and Z. Mallat, 'Leukocyte-Derived Interleukin 10 Is Required for Protection against 
Atherosclerosis in Low-Density Lipoprotein Receptor Knockout Mice', Arterioscler 
Thromb Vasc Biol, 24 (2004), 1474-8. 
189 H. Qi, 'T Follicular Helper Cells in Space-Time', Nat Rev Immunol, 16 (2016), 612-25. 
 62 
190 F. J. Quintana, and I. R. Cohen, 'The Natural Autoantibody Repertoire and 
Autoimmune Disease', Biomed Pharmacother, 58 (2004), 276-81. 
191 E. J. Rahn, T. Iannitti, R. R. Donahue, and B. K. Taylor, 'Sex Differences in a Mouse 
Model of Multiple Sclerosis: Neuropathic Pain Behavior in Females but Not Males and 
Protection from Neurological Deficits During Proestrus', Biol Sex Differ, 5 (2014), 4. 
192 D. J. Rawlings, M. A. Schwartz, S. W. Jackson, and A. Meyer-Bahlburg, 'Integration 
of B Cell Responses through Toll-Like Receptors and Antigen Receptors', Nat Rev 
Immunol, 12 (2012), 282-94. 
193 A. Ray, M. K. Mann, S. Basu, and B. N. Dittel, 'A Case for Regulatory B Cells in 
Controlling the Severity of Autoimmune-Mediated Inflammation in Experimental 
Autoimmune Encephalomyelitis and Multiple Sclerosis', J Neuroimmunol, 230 (2011), 
1-9. 
194 I. Domingo R. Revilla, I. Bilic, B. Vilagos, H. Tagoh, A. Ebert, I. M. Tamir, L. Smeenk, 
J. Trupke, A. Sommer, M. Jaritz, and M. Busslinger, 'The B-Cell Identity Factor Pax5 
Regulates Distinct Transcriptional Programmes in Early and Late B Lymphopoiesis', 
EMBO J, 31 (2012), 3130-46. 
195 C. Ribeiro de Almeida, R. Stadhouders, M. J. de Bruijn, I. M. Bergen, S. Thongjuea, 
B. Lenhard, W. van Ijcken, F. Grosveld, N. Galjart, E. Soler, and R. W. Hendriks, 'The 
DNA-Binding Protein Ctcf Limits Proximal Vkappa Recombination and Restricts 
Kappa Enhancer Interactions to the Immunoglobulin Kappa Light Chain Locus', 
Immunity, 35 (2011), 501-13. 
196 A. P. Robinson, C. T. Harp, A. Noronha, and S. D. Miller, 'The Experimental 
Autoimmune Encephalomyelitis (Eae) Model of Ms: Utility for Understanding Disease 
Pathophysiology and Treatment', Handb Clin Neurol, 122 (2014), 173-89. 
197 A. G. Rolink, J. Andersson, and F. Melchers, 'Characterization of Immature B Cells by 
a Novel Monoclonal Antibody, by Turnover and by Mitogen Reactivity', Eur J 
Immunol, 28 (1998), 3738-48. 
198 A. G. Rolink, T. Brocker, H. Bluethmann, M. H. Kosco-Vilbois, J. Andersson, and F. 
Melchers, 'Mutations Affecting Either Generation or Survival of Cells Influence the 
Pool Size of Mature B Cells', Immunity, 10 (1999), 619-28. 
199 A. G. Rolink, C. Schaniel, M. Busslinger, S. L. Nutt, and F. Melchers, 'Fidelity and 
Infidelity in Commitment to B-Lymphocyte Lineage Development', Immunol Rev, 175 
(2000), 104-11. 
200 A. G. Rolink, J. Tschopp, P. Schneider, and F. Melchers, 'Baff Is a Survival and 
Maturation Factor for Mouse B Cells', Eur J Immunol, 32 (2002), 2004-10. 
201 J. Ronnelid, J. Lysholm, A. Engstrom-Laurent, L. Klareskog, and B. Heyman, 'Local 
Anti-Type Ii Collagen Antibody Production in Rheumatoid Arthritis Synovial Fluid. 
  63 
Evidence for an Hla-Dr4-Restricted Igg Response', Arthritis Rheum, 37 (1994), 1023-
9. 
202 S. M. Rosenfeld, H. M. Perry, A. Gonen, T. A. Prohaska, P. Srikakulapu, S. Grewal, 
D. Das, C. McSkimming, A. M. Taylor, S. Tsimikas, T. P. Bender, J. L. Witztum, and 
C. A. McNamara, 'B-1b Cells Secrete Atheroprotective Igm and Attenuate 
Atherosclerosis', Circ Res, 117 (2015), e28-39. 
203 E. Rosjo, L. H. Steffensen, L. Jorgensen, J. C. Lindstrom, J. Saltyte Benth, A. E. 
Michelsen, P. Aukrust, T. Ueland, M. T. Kampman, O. Torkildsen, and T. Holmoy, 
'Vitamin D Supplementation and Systemic Inflammation in Relapsing-Remitting 
Multiple Sclerosis', J Neurol, 262 (2015), 2713-21. 
204 R. Ross, 'Atherosclerosis--an Inflammatory Disease', N Engl J Med, 340 (1999), 115-
26. 
205 M. Rowley, B. Tait, I. R. Mackay, T. Cunningham, and B. Phillips, 'Collagen 
Antibodies in Rheumatoid Arthritis. Significance of Antibodies to Denatured Collagen 
and Their Association with Hla-Dr4', Arthritis Rheum, 29 (1986), 174-84. 
206 K. A. Saadat, '[Role of Arid3a in E2f Target Gene Expression and Cell Growth]', 
Kokubyo Gakkai Zasshi, 80 (2013), 15-20. 
207 A. P. Sage, M. Nus, L. L. Baker, A. J. Finigan, L. M. Masters, and Z. Mallat, 
'Regulatory B Cell-Specific Interleukin-10 Is Dispensable for Atherosclerosis 
Development in Mice', Arterioscler Thromb Vasc Biol, 35 (2015), 1770-3. 
208 J. Salzer, G. Hallmans, M. Nystrom, H. Stenlund, G. Wadell, and P. Sundstrom, 
'Smoking as a Risk Factor for Multiple Sclerosis', Mult Scler, 19 (2013), 1022-7. 
209 H. P. Savage, and N. Baumgarth, 'Characteristics of Natural Antibody-Secreting Cells', 
Ann N Y Acad Sci, 1362 (2015), 132-42. 
210 S. Sawcer, 'The Major Cause of Multiple Sclerosis Is Environmental: Genetics Has a 
Minor Role--No', Mult Scler, 17 (2011), 1174-5. 
211 S. Sawcer, R. J. Franklin, and M. Ban, 'Multiple Sclerosis Genetics', Lancet Neurol, 13 
(2014), 700-9. 
212 S. Sayols-Baixeras, C. Lluis-Ganella, G. Lucas, and R. Elosua, 'Pathogenesis of 
Coronary Artery Disease: Focus on Genetic Risk Factors and Identification of Genetic 
Variants', Appl Clin Genet, 7 (2014), 15-32. 
213 C. Schmidt, D. Kim, G. C. Ippolito, H. R. Naqvi, L. Probst, S. Mathur, G. Rosas-
Acosta, V. G. Wilson, A. L. Oldham, M. Poenie, C. F. Webb, and P. W. Tucker, 
'Signalling of the Bcr Is Regulated by a Lipid Rafts-Localised Transcription Factor, 
Bright', EMBO J, 28 (2009), 711-24. 
 64 
214 A. E. Schroder, A. Greiner, C. Seyfert, and C. Berek, 'Differentiation of B Cells in the 
Nonlymphoid Tissue of the Synovial Membrane of Patients with Rheumatoid Arthritis', 
Proc Natl Acad Sci U S A, 93 (1996), 221-5. 
215 E. Schurgers, A. Billiau, and P. Matthys, 'Collagen-Induced Arthritis as an Animal 
Model for Rheumatoid Arthritis: Focus on Interferon-Gamma', J Interferon Cytokine 
Res, 31 (2011), 917-26. 
216 W. Seo, T. Ikawa, H. Kawamoto, and I. Taniuchi, 'Runx1-Cbfbeta Facilitates Early B 
Lymphocyte Development by Regulating Expression of Ebf1', J Exp Med, 209 (2012), 
1255-62. 
217 M. Shankar, J. C. Nixon, S. Maier, J. Workman, A. D. Farris, and C. F. Webb, 'Anti-
Nuclear Antibody Production and Autoimmunity in Transgenic Mice That Overexpress 
the Transcription Factor Bright', J Immunol, 178 (2007), 2996-3006. 
218 H. Singh, K. L. Medina, and J. M. Pongubala, 'Contingent Gene Regulatory Networks 
and B Cell Fate Specification', Proc Natl Acad Sci U S A, 102 (2005), 4949-53. 
219 J. A. Singh, R. Christensen, G. A. Wells, M. E. Suarez-Almazor, R. Buchbinder, M. A. 
Lopez-Olivo, E. T. Ghogomu, and P. Tugwell, 'A Network Meta-Analysis of 
Randomized Controlled Trials of Biologics for Rheumatoid Arthritis: A Cochrane 
Overview', CMAJ, 181 (2009), 787-96. 
220 J. D. Smith, D. James, H. M. Dansky, K. M. Wittkowski, K. J. Moore, and J. L. 
Breslow, 'In Silico Quantitative Trait Locus Map for Atherosclerosis Susceptibility in 
Apolipoprotein E-Deficient Mice', Arterioscler Thromb Vasc Biol, 23 (2003), 117-22. 
221 J. Sokolove, R. Bromberg, K. D. Deane, L. J. Lahey, L. A. Derber, P. E. Chandra, J. D. 
Edison, W. R. Gilliland, R. J. Tibshirani, J. M. Norris, V. M. Holers, and W. H. 
Robinson, 'Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts 
Progression to Rheumatoid Arthritis', PLoS One, 7 (2012), e35296. 
222 W. Stohl, J. Gomez-Reino, E. Olech, J. Dudler, R. M. Fleischmann, C. A. Zerbini, A. 
Ashrafzadeh, S. Grzeschik, R. Bieraugel, J. Green, S. Francom, and W. Dummer, 
'Safety and Efficacy of Ocrelizumab in Combination with Methotrexate in Mtx-Naive 
Subjects with Rheumatoid Arthritis: The Phase Iii Film Trial', Ann Rheum Dis, 71 
(2012), 1289-96. 
223 R. H. Straub, 'The Complex Role of Estrogens in Inflammation', Endocr Rev, 28 (2007), 
521-74. 
224 A. C. Strom, A. J. Cross, J. E. Cole, P. A. Blair, C. Leib, M. E. Goddard, E. C. Rosser, 
I. Park, A. Hultgardh Nilsson, J. Nilsson, C. Mauri, and C. Monaco, 'B Regulatory Cells 
Are Increased in Hypercholesterolaemic Mice and Protect from Lesion Development 
Via Il-10', Thromb Haemost, 114 (2015), 835-47. 
225 A. Suzuki, and K. Yamamoto, 'From Genetics to Functional Insights into Rheumatoid 
Arthritis', Clin Exp Rheumatol, 33 (2015), S40-3. 
  65 
226 L. Svensson, J. Jirholt, R. Holmdahl, and L. Jansson, 'B Cell-Deficient Mice Do Not 
Develop Type Ii Collagen-Induced Arthritis (Cia)', Clin Exp Immunol, 111 (1998), 521-
6. 
227 I. Tabas, K. J. Williams, and J. Boren, 'Subendothelial Lipoprotein Retention as the 
Initiating Process in Atherosclerosis: Update and Therapeutic Implications', 
Circulation, 116 (2007), 1832-44. 
228 S. Takemura, A. Braun, C. Crowson, P. J. Kurtin, R. H. Cofield, W. M. O'Fallon, J. J. 
Goronzy, and C. M. Weyand, 'Lymphoid Neogenesis in Rheumatoid Synovitis', J 
Immunol, 167 (2001), 1072-80. 
229 A. Tarkowski, L. Klareskog, H. Carlsten, P. Herberts, and W. J. Koopman, 'Secretion 
of Antibodies to Types I and Ii Collagen by Synovial Tissue Cells in Patients with 
Rheumatoid Arthritis', Arthritis Rheum, 32 (1989), 1087-92. 
230 P. C. Taylor, E. Quattrocchi, S. Mallett, R. Kurrasch, J. Petersen, and D. J. Chang, 
'Ofatumumab, a Fully Human Anti-Cd20 Monoclonal Antibody, in Biological-Naive, 
Rheumatoid Arthritis Patients with an Inadequate Response to Methotrexate: A 
Randomised, Double-Blind, Placebo-Controlled Clinical Trial', Ann Rheum Dis, 70 
(2011), 2119-25. 
231 E. ten Boekel, F. Melchers, and A. G. Rolink, 'Precursor B Cells Showing H Chain 
Allelic Inclusion Display Allelic Exclusion at the Level of Pre-B Cell Receptor Surface 
Expression', Immunity, 8 (1998), 199-207. 
232 D. Teupser, M. Tan, A. D. Persky, and J. L. Breslow, 'Atherosclerosis Quantitative 
Trait Loci Are Sex- and Lineage-Dependent in an Intercross of C57bl/6 and Fvb/N 
Low-Density Lipoprotein Receptor-/- Mice', Proc Natl Acad Sci U S A, 103 (2006), 
123-8. 
233 J. Tian, D. Zekzer, L. Hanssen, Y. Lu, A. Olcott, and D. L. Kaufman, 
'Lipopolysaccharide-Activated B Cells Down-Regulate Th1 Immunity and Prevent 
Autoimmune Diabetes in Nonobese Diabetic Mice', J Immunol, 167 (2001), 1081-9. 
234 S. Tonegawa, '[Molecular Biology of Immunologic Recognition]', Tanpakushitsu 
Kakusan Koso, 32 (1987), 239-50. 
235 C. Torring, C. Andreasen, N. Gehr, L. Bjerg, T. Petersen, and P. Hollsberg, 'Higher 
Incidence of Epstein-Barr Virus-Induced Lymphocyte Transformation in Multiple 
Sclerosis', Acta Neurol Scand, 130 (2014), 90-6. 
236 D. E. Trentham, A. S. Townes, and A. H. Kang, 'Autoimmunity to Type Ii Collagen an 
Experimental Model of Arthritis', J Exp Med, 146 (1977), 857-68. 
237 M. Tsuneto, K. Tokoyoda, E. Kajikhina, A. E. Hauser, T. Hara, S. Tani-Ichi, K. Ikuta, 
and F. Melchers, 'B-Cell Progenitors and Precursors Change Their Microenvironment 
in Fetal Liver During Early Development', Stem Cells, 31 (2013), 2800-12. 
 66 
238 K. S. Tudor, K. J. Payne, Y. Yamashita, and P. W. Kincade, 'Functional Assessment of 
Precursors from Murine Bone Marrow Suggests a Sequence of Early B Lineage 
Differentiation Events', Immunity, 12 (2000), 335-45. 
239 C. A. Turner, Jr., D. H. Mack, and M. M. Davis, 'Blimp-1, a Novel Zinc Finger-
Containing Protein That Can Drive the Maturation of B Lymphocytes into 
Immunoglobulin-Secreting Cells', Cell, 77 (1994), 297-306. 
240 M. Vallespinos, D. Fernandez, L. Rodriguez, J. Alvaro-Blanco, E. Baena, M. Ortiz, D. 
Dukovska, D. Martinez, A. Rojas, M. R. Campanero, and I. Moreno de Alboran, 'B 
Lymphocyte Commitment Program Is Driven by the Proto-Oncogene C-Myc', J 
Immunol, 186 (2011), 6726-36. 
241 J. A. Van Ziffle, and C. A. Lowell, 'Neutrophil-Specific Deletion of Syk Kinase Results 
in Reduced Host Defense to Bacterial Infection', Blood, 114 (2009), 4871-82. 
242 Y. Y. Wang, Q. Wang, X. H. Sun, R. Z. Liu, Y. Shu, T. Kanekura, J. H. Huang, Y. P. 
Li, J. C. Wang, M. Zhao, Q. J. Lu, and R. Xiao, 'DNA Hypermethylation of the 
Forkhead Box Protein 3 (Foxp3) Promoter in Cd4+ T Cells of Patients with Systemic 
Sclerosis', Br J Dermatol, 171 (2014), 39-47. 
243 Y. Wang, Y. Yang, Y. Luo, Y. Yin, Q. Wang, Y. Li, T. Kanekura, J. Wang, G. Liang, 
M. Zhao, Q. Lu, and R. Xiao, 'Aberrant Histone Modification in Peripheral Blood B 
Cells from Patients with Systemic Sclerosis', Clin Immunol, 149 (2013), 46-54. 
244 J. M. Ward, K. Rose, C. Montgomery, I. Adrianto, J. A. James, J. T. Merrill, and C. F. 
Webb, 'Disease Activity in Systemic Lupus Erythematosus Correlates with Expression 
of the Transcription Factor at-Rich-Interactive Domain 3a', Arthritis Rheumatol, 66 
(2014), 3404-12. 
245 R. Watanabe, N. Ishiura, H. Nakashima, Y. Kuwano, H. Okochi, K. Tamaki, S. Sato, 
T. F. Tedder, and M. Fujimoto, 'Regulatory B Cells (B10 Cells) Have a Suppressive 
Role in Murine Lupus: Cd19 and B10 Cell Deficiency Exacerbates Systemic 
Autoimmunity', J Immunol, 184 (2010), 4801-9. 
246 C. F. Webb, J. Bryant, M. Popowski, L. Allred, D. Kim, J. Harriss, C. Schmidt, C. A. 
Miner, K. Rose, H. L. Cheng, C. Griffin, and P. W. Tucker, 'The Arid Family 
Transcription Factor Bright Is Required for Both Hematopoietic Stem Cell and B 
Lineage Development', Mol Cell Biol, 31 (2011), 1041-53. 
247 C. F. Webb, C. Das, R. L. Coffman, and P. W. Tucker, 'Induction of Immunoglobulin 
Mu Mrna in a B Cell Transfectant Stimulated with Interleukin-5 and a T-Dependent 
Antigen', J Immunol, 143 (1989), 3934-9. 
248 C. F. Webb, C. Das, S. Eaton, K. Calame, and P. W. Tucker, 'Novel Protein-DNA 
Interactions Associated with Increased Immunoglobulin Transcription in Response to 
Antigen Plus Interleukin-5', Mol Cell Biol, 11 (1991), 5197-205. 
  67 
249 C. F. Webb, C. Das, K. L. Eneff, and P. W. Tucker, 'Identification of a Matrix-
Associated Region 5' of an Immunoglobulin Heavy Chain Variable Region Gene', Mol 
Cell Biol, 11 (1991), 5206-11. 
250 C. F. Webb, E. A. Smith, K. L. Medina, K. L. Buchanan, G. Smithson, and S. Dou, 
'Expression of Bright at Two Distinct Stages of B Lymphocyte Development', J 
Immunol, 160 (1998), 4747-54. 
251 C. F. Webb, Y. Yamashita, N. Ayers, S. Evetts, Y. Paulin, M. E. Conley, and E. A. 
Smith, 'The Transcription Factor Bright Associates with Bruton's Tyrosine Kinase, the 
Defective Protein in Immunodeficiency Disease', J Immunol, 165 (2000), 6956-65. 
252 E. Welinder, J. Ahsberg, and M. Sigvardsson, 'B-Lymphocyte Commitment: 
Identifying the Point of No Return', Semin Immunol, 23 (2011), 335-40. 
253 S. C. Whitman, P. Ravisankar, H. Elam, and A. Daugherty, 'Exogenous Interferon-
Gamma Enhances Atherosclerosis in Apolipoprotein E-/- Mice', Am J Pathol, 157 
(2000), 1819-24. 
254 S. M. Vieira, H. P. Lemos, R. Grespan, M. H. Napimoga, D. Dal-Secco, A. Freitas, T. 
M. Cunha, W. A. Verri, Jr., D. A. Souza-Junior, M. C. Jamur, K. S. Fernandes, C. 
Oliver, J. S. Silva, M. M. Teixeira, and F. Q. Cunha, 'A Crucial Role for Tnf-Alpha in 
Mediating Neutrophil Influx Induced by Endogenously Generated or Exogenous 
Chemokines, Kc/Cxcl1 and Lix/Cxcl5', Br J Pharmacol, 158 (2009), 779-89. 
255 L. M. Villar, J. Masjuan, P. Gonzalez-Porque, J. Plaza, M. C. Sadaba, E. Roldan, A. 
Bootello, and J. C. Alvarez-Cermeno, 'Intrathecal Igm Synthesis in Neurologic 
Diseases: Relationship with Disability in Ms', Neurology, 58 (2002), 824-6. 
256 D. Wilsker, L. Probst, H. M. Wain, L. Maltais, P. W. Tucker, and E. Moran, 
'Nomenclature of the Arid Family of DNA-Binding Proteins', Genomics, 86 (2005), 
242-51. 
257 C. G. Vinuesa, I. Sanz, and M. C. Cook, 'Dysregulation of Germinal Centres in 
Autoimmune Disease', Nat Rev Immunol, 9 (2009), 845-57. 
258 S. D. Wolf, B. N. Dittel, F. Hardardottir, and C. A. Janeway, Jr., 'Experimental 
Autoimmune Encephalomyelitis Induction in Genetically B Cell-Deficient Mice', J Exp 
Med, 184 (1996), 2271-8. 
259 P. H. Wooley, 'Collagen-Induced Arthritis in the Mouse', Methods Enzymol, 162 
(1988), 361-73. 
260 P. H. Wooley, H. S. Luthra, M. M. Griffiths, J. M. Stuart, A. Huse, and C. S. David, 
'Type Ii Collagen-Induced Arthritis in Mice. Iv. Variations in Immunogenetic 
Regulation Provide Evidence for Multiple Arthritogenic Epitopes on the Collagen 
Molecule', J Immunol, 135 (1985), 2443-51. 
 68 
261 P. H. Wooley, H. S. Luthra, J. M. Stuart, and C. S. David, 'Type Ii Collagen-Induced 
Arthritis in Mice. I. Major Histocompatibility Complex (I Region) Linkage and 
Antibody Correlates', J Exp Med, 154 (1981), 688-700. 
262 K. Wouters, R. Shiri-Sverdlov, P. J. van Gorp, M. van Bilsen, and M. H. Hofker, 
'Understanding Hyperlipidemia and Atherosclerosis: Lessons from Genetically 
Modified Apoe and Ldlr Mice', Clin Chem Lab Med, 43 (2005), 470-9. 
263 J. M. Vyas, A. G. Van der Veen, and H. L. Ploegh, 'The Known Unknowns of Antigen 
Processing and Presentation', Nat Rev Immunol, 8 (2008), 607-18. 
264 K. Yanaba, J. D. Bouaziz, K. M. Haas, J. C. Poe, M. Fujimoto, and T. F. Tedder, 'A 
Regulatory B Cell Subset with a Unique Cd1dhicd5+ Phenotype Controls T Cell-
Dependent Inflammatory Responses', Immunity, 28 (2008), 639-50. 
265 M. Yang, K. Rui, S. Wang, and L. Lu, 'Regulatory B Cells in Autoimmune Diseases', 
Cell Mol Immunol, 10 (2013), 122-32. 
266 X. Yang, L. Peterson, R. Thieringer, J. L. Deignan, X. Wang, J. Zhu, S. Wang, H. 
Zhong, S. Stepaniants, J. Beaulaurier, I. M. Wang, R. Rosa, A. M. Cumiskey, J. M. 
Luo, Q. Luo, K. Shah, J. Xiao, D. Nickle, A. Plump, E. E. Schadt, A. J. Lusis, and P. 
Y. Lum, 'Identification and Validation of Genes Affecting Aortic Lesions in Mice', J 
Clin Invest, 120 (2010), 2414-22. 
267 A. Yarwood, T. W. Huizinga, and J. Worthington, 'The Genetics of Rheumatoid 
Arthritis: Risk and Protection in Different Stages of the Evolution of Ra', Rheumatology 
(Oxford), 55 (2016), 199-209. 
268 B. H. Ye, G. Cattoretti, Q. Shen, J. Zhang, N. Hawe, R. de Waard, C. Leung, M. Nouri-
Shirazi, A. Orazi, R. S. Chaganti, P. Rothman, A. M. Stall, P. P. Pandolfi, and R. Dalla-
Favera, 'The Bcl-6 Proto-Oncogene Controls Germinal-Centre Formation and Th2-
Type Inflammation', Nat Genet, 16 (1997), 161-70. 
269 T. A. Yednock, C. Cannon, L. C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin, 
'Prevention of Experimental Autoimmune Encephalomyelitis by Antibodies against 
Alpha 4 Beta 1 Integrin', Nature, 356 (1992), 63-6. 
270 T. Yokota, T. Sudo, T. Ishibashi, Y. Doi, M. Ichii, K. Orirani, and Y. Kanakura, 
'Complementary Regulation of Early B-Lymphoid Differentiation by Genetic and 
Epigenetic Mechanisms', Int J Hematol, 98 (2013), 382-9. 
271 T. Yoshida, S. Y. Ng, J. C. Zuniga-Pflucker, and K. Georgopoulos, 'Early 
Hematopoietic Lineage Restrictions Directed by Ikaros', Nat Immunol, 7 (2006), 382-
91. 
272 J. Yuan, C. K. Nguyen, X. Liu, C. Kanellopoulou, and S. A. Muljo, 'Lin28b 
Reprograms Adult Bone Marrow Hematopoietic Progenitors to Mediate Fetal-Like 
Lymphopoiesis', Science, 335 (2012), 1195-200. 
  69 
273 S. Yurasov, H. Wardemann, J. Hammersen, M. Tsuiji, E. Meffre, V. Pascual, and M. 
C. Nussenzweig, 'Defective B Cell Tolerance Checkpoints in Systemic Lupus 
Erythematosus', J Exp Med, 201 (2005), 703-11. 
274 S. Zandi, R. Mansson, P. Tsapogas, J. Zetterblad, D. Bryder, and M. Sigvardsson, 'Ebf1 
Is Essential for B-Lineage Priming and Establishment of a Transcription Factor 
Network in Common Lymphoid Progenitors', J Immunol, 181 (2008), 3364-72. 
275 A. Zhernakova, S. Withoff, and C. Wijmenga, 'Clinical Implications of Shared Genetics 
and Pathogenesis in Autoimmune Diseases', Nat Rev Endocrinol, 9 (2013), 646-59. 
276 Q. Zhou, H. Wang, D. M. Schwartz, M. Stoffels, Y. H. Park, Y. Zhang, D. Yang, E. 
Demirkaya, M. Takeuchi, W. L. Tsai, J. J. Lyons, X. Yu, C. Ouyang, C. Chen, D. T. 
Chin, K. Zaal, S. C. Chandrasekharappa, P. Hanson E, Z. Yu, J. C. Mullikin, S. A. 
Hasni, I. E. Wertz, A. K. Ombrello, D. L. Stone, P. Hoffmann, A. Jones, B. K. Barham, 
H. L. Leavis, A. van Royen-Kerkof, C. Sibley, E. D. Batu, A. Gul, R. M. Siegel, M. 
Boehm, J. D. Milner, S. Ozen, M. Gadina, J. Chae, R. M. Laxer, D. L. Kastner, and I. 
Aksentijevich, 'Loss-of-Function Mutations in Tnfaip3 Leading to A20 
Haploinsufficiency Cause an Early-Onset Autoinflammatory Disease', Nat Genet, 48 
(2016), 67-73. 
277 Y. Zhou, Y. S. Li, S. R. Bandi, L. Tang, S. A. Shinton, K. Hayakawa, and R. R. Hardy, 
'Lin28b Promotes Fetal B Lymphopoiesis through the Transcription Factor Arid3a', J 
Exp Med, 212 (2015), 569-80. 
278 A. Zmuidzinas, K. D. Fischer, S. A. Lira, L. Forrester, S. Bryant, A. Bernstein, and M. 
Barbacid, 'The Vav Proto-Oncogene Is Required Early in Embryogenesis but Not for 
Hematopoietic Development in Vitro', EMBO J, 14 (1995), 1-11. 
 
